

## Preface

The volume of information that today's OB/GYN practitioner needs to know is staggering and growing rapidly because of new basic research and clinical discoveries made daily. There is a critical need for both medical students and practicing physicians to have easy access to relevant information in a concise and carefully organized manner. This goal is difficult to achieve because 21st century medicine is characterized by a vast quantity of clinically relevant information. That is why the goal of this textbook is to clearly and concisely present the *essential* knowledge needed to practice state-of-the-art obstetric and gynecologic medicine.

Women's health and the field of obstetrics and gynecology are critically important to the overall health of every society. Indeed, the health of women and their newborn children are key determinants of the potential of a society for advancing. The Association of Professors of Gynecology and Obstetrics has developed consensus learning objectives for medical students on clinical rotations in obstetrics and gynecology. These objectives, modified to focus on the most important and common clinical problems, are the basis for the extensive amount of material presented in this handbook.

Each chapter is presented in a clear, consistent manner and, where appropriate, begins with the definition of a particular condition, its common manifestations, and

how it is routinely diagnosed. This is followed by a discussion of the prevalence and epidemiology of the condition, its etiology and pathophysiology, detailed information about the methods and protocols for its screening and/or detection, and the most recent, evidence-based information about its management. Each chapter uses photographs, tables, and other figures to present critical data and ideas, and ends by emphasizing the key clinical points. Within most chapters, an "Evidence" box is included to provide readers with exposure to how high-quality research information is used to guide clinical diagnosis and treatment. These "Evidence" boxes provide the kind of clinical information that inform the modern practice of OB/GYN medicine.

Medical students do not learn by a bolus infusion of a massive quantity of information. Rather, they learn through a continuous cycle of reading, thinking, talking, and doing. The purpose of this handbook is to assist the student and practitioner in this constant cycle of life-long learning and, more importantly, to offer the most evidence-based approach to the diagnosis and treatment of real OB/GYN patient problems.

*E. Albert Reece, MD, PhD, MBA  
Robert L. Barbieri, MD*

## The Menstrual Cycle

The menstrual cycle can be divided into three phases:

1. Follicular phase
2. Ovulation
3. Luteal phase


### Follicular Phase

Follicular development is a dynamic process designed to allow the monthly recruitment of a cohort of follicles, and the selection of one dominant follicle that will release a single mature oocyte each month.

In humans, the average length of the follicular phase ranges from 10 to 14 days (**Fig. 4.1**), and variability in this length is responsible for most of the variation in total cycle length. The follicular phase initiates at the first day of the menses. At this time the levels of gonadal steroids are low, and with the demise of the corpus luteum follicle-stimulating hormone (FSH) levels begin to rise recruiting a cohort of follicles.

In response to FSH, the follicles initiate the secretion of estrogen, which increases through the follicular phase and is responsible for endometrial growth. The rise in estrogen exerts a negative feedback on FSH at the hypophysis (pituitary gland) level.

In addition, the growing follicles produce inhibin B, which also suppresses FSH secretion by the pituitary.



**Fig. 4.1** A diagram of the menstrual cycle. The follicular phase constitutes the period beginning with menstruation and ending at ovulation, which is approximately 14 days in most women.

Conversely, the rise in estrogen levels at the beginning of the cycle produces a negative effect on the secretion of luteinizing hormone (LH), but late in the follicular phase LH levels increase dramatically.

During the follicular phase, hormonal feedback promotes the orderly development of a single dominant follicle, which is destined to ovulate from a period of initial growth of a primordial follicle through the stages of the preantral, antral, and preovulatory follicular growth (**Fig. 4.2**).

This phase corresponds to the proliferative phase in the uterus, in which there is building of the endometrial lining. In the middle of the follicular phase of menstrual cycle, after growth of a follicle has been achieved, local concentrations of prostaglandins and proteolytic enzymes induce the extrusion of the oocyte through the follicular wall, and ovulation occurs.

After ovulation, the menstrual cycle enters the luteal phase, the ruptured follicle becomes the corpus luteum and secretion of both progesterone and estrogen provide the adequate environment for the fertilized oocyte to implant in the endometrium. This phase corresponds to the secretory phase in the uterus.

If fertilization occurs, the secretion of human chorionic gonadotropin (HCG) by the embryo rescues the corpus luteum, allowing the continued secretion of progesterone and estrogen to sustain the pregnancy. If fertilization does not occur, the corpus luteum dies, which causes a drop in progesterone and estrogen levels and eventual shedding of the endometrium (menses).


### Ovarian Follicular Development

Most oogonia are lost during fetal development, and the remaining follicles are recruited during the reproductive years until menopause occurs, in which the oocyte reserve is depleted.


During fetal development, the oogonia are arrested at the diplotene stage of the prophase in the first meiosis, the germ-cell process of reduction division. At this stage, a single layer of 8 to 10 granulosa cells surrounds the oogonia to form the primordial follicle. Those oogonia that fail to be properly surrounded by granulosa cells undergo atresia.

When the developing oogonia begin to enter the meiotic prophase I, they are known as primary follicles (**Fig. 4.3**), or oocytes, and remain arrested in this phase, until the time of ovulation, by a probable stasis mechanism involving an oocyte maturation inhibitor (OMI) produced by granulosa cells.

It is believed that the inhibitory action of this substance is achieved via gap junctions connecting the oocyte to its surrounding granulosa cells. When the LH surge at midcycle occurs, the gap junctions are disrupted, and the connection between the oocyte and granulosa cells is interrupted, allowing meiosis I to resume.




**Fig. 4.2** Folliculogenesis and the classes of growing follicles in the human ovary. The early stages of folliculogenesis proceed very slowly, and it has been estimated that in humans the process can take more than 300 days. Even in the preantral stage (class 1), many growing follicles fail to survive, and degenerate through a process termed follicular atresia. Growing follicles enter class 2 usually in the late luteal phase, class 3 between late luteal and early follicular phases, class 4 during late follicular phase, and become recruitable class 5 follicles during late luteal phase.



**Fig. 4.3** The life cycle of a follicle.

### Primordial Follicles

In each cycle there is growth of a cohort of oocytes. The initial recruitment and growth of the primordial follicles is independent of gonadotropin and affects a cohort over several months. The factor(s) responsible for the recruitment in each cycle is unknown. After initial recruitment, control of follicular growth and differentiation shifts from gonadotropin-independent to gonadotropin-dependent growth, presumably by FSH. The action of FSH promotes growth of the oocyte and expansion of the granulosa cells (**Fig. 4.4**) from a single layer to a multilayer of cuboidal cells.



**Fig. 4.4** A human oocyte with surrounding granulosa cells, after aspiration.

### Preantral Follicle

Driven by the stimulus of FSH, the zona pellucida, a glycoprotein-rich substance, is formed, which separates the oocyte from the surrounding granulosa cells. Simultaneously with the proliferation of granulosa cells, there is proliferation of theca cells in the stroma bordering the granulosa. Both granulosa and theca cells function synergistically to produce estrogen, which is then secreted into the circulation. One of the follicles attains dominance over the rest of the cohort, which undergo atresia.

The mechanism for selection of the dominant follicle is still not clear, but follicular development can be explained by the “two-cell, two-gonadotropin theory,” which states that during follicle development, steroid hormone synthesis takes place in a compartmentalized

## 6 Pap Smear and Human Papilloma Virus Testing

*Benjamin Piura and Ruthy Shaco-Levy*

After breast cancer, cervical cancer is the second most common malignancy diagnosed in women worldwide. Approximately 500 000 new cases of cervical cancer are diagnosed each year, and nearly 250 000 women die of this disease each year worldwide.

Cervical cancer is the most common malignancy encountered in women in developing countries. The majority of these cases occur in countries with limited or no effective screening programs using the Papanicolaou (Pap) smear test<sup>1</sup> for detecting cervical cellular abnormalities, which places women at a greater risk for developing cervical cancer. In the United States, Finland, Sweden, Iceland, and other developed countries where Pap smear screening is widely used, rates of cervical cancer have noticeably dropped up to 50% over the past 20–30 years (see Evidence Box 6.1).

However, health disparities prevent more lives from being saved with Pap smear screening, even in developed countries. Indeed, despite the test's widespread availability in the United States, for example, more than 10 000 new cases of cervical cancer are diagnosed each year, and almost 4000 women die each year unnecessarily from this preventable disease. About 50% of women with cervical cancer in the United States did not have a Pap smear test in the preceding 3 years, and an additional 10% had not been screened in the past 5 years.

Nevertheless, more than 50 million Pap smears are performed each year in the United States alone, and 7% (3.5 million) of these give abnormal test results. It has been estimated that women who never had a Pap smear have a 3.5% risk of developing cervical cancer, whereas the risk is reduced to 0.8% with Pap smear screening. Since infection with human papilloma virus (HPV) has

been found in almost all cervical cancers, testing for the presence of high-risk HPV types in cervical samples has now become a part of routine clinical work-up in women with equivocal Pap smear test results.

### Pap Smear Terminology

There are a number of outdated terminologies regarding Pap smear results (**Table 6.1**). The lack of a common terminology initially resulted in widespread confusion about what really constitutes an abnormal test result. This confusion necessitated further action. In December 1988, a National Cancer Institute workshop held in Bethesda, Maryland, provided for the first time a consensus, now known as the Bethesda System, on how to properly read Pap smears. The result was initial guidelines designed to decrease the variability among laboratories reporting the results.

The three most important contributions of this Bethesda System were:

1. Establishing a special category of abnormal squamous cells of undetermined significance (ASCUS)
2. Organizing the four grades of atypical squamous cells (mild, moderate, severe, and carcinoma in situ) of the old classifications into two distinctive groups: low-

**Table 6.1** Historical Pap smear terminology

Papanicolaou	United States	United Kingdom
Normal	Normal	Normal
Inflammatory	Inflammatory	Inflammatory
Atypical cells	Mild atypia Moderate atypia	Mild dyskariosis Moderate dyskariosis
Carcinoma in situ	Severe atypia	Severe dyskariosis
Carcinoma	Carcinoma	Carcinoma

<sup>1</sup> In 1928, George Papanicolaou began sampling vaginal cells, speculating that the presence of any atypical cells might predict the development of cervical cancer. It was only in 1943 when he and Herbert Traut published a monograph on the topic that the Papanicolaou (Pap) smear became the standard cervical cancer screening test. In 1947, Ayers introduced a specially designed wooden spatula (Ayer spatula) for the direct collection of cells from the uterine cervix.

grade squamous intra-epithelial lesion (LSIL) (Fig. 6.4), and high-grade squamous intra-epithelial lesion (HSIL) (Fig. 6.5). LSIL (previously referred to as “mild atypia”) is compatible with grade 1 cervical intraepithelial neoplasia (CIN 1) and HSIL (encompassing “moderate atypia,” “severe atypia,” and “carcinoma in situ”) is compatible with grade 2 or 3 cervical intra-epithelial neoplasia (CIN 2, 3) and carcinoma in situ (CIS)

3. Establishing a new category of abnormal glandular cells of undetermined significance (AGCUS)

## Key Terminology Changes in the 2001 Bethesda System

The Bethesda System was revised in 1991 and 2001. The 2001 Bethesda System (Table 6.2) reflects the most current knowledge about the biology of Pap test abnormalities and addresses new screening technologies such as the liquid-based, thin-layer Pap smear and HPV testing. It recommends dividing the category of atypical squamous cells (ASCs) into two subcategories: a) atypical squamous cells of undetermined significance (ASCUS), and b) atypical squamous cells that cannot exclude high-grade intra-epithelial lesion (ASC-H).

Overall, among all women with ASC, the risk of developing invasive cancer is low (0.1–0.2%). Nevertheless, the prevalence of CIN 2, 3 confirmed by biopsy among women with ASC is 7–12%, whereas the prevalence of CIN 2, 3 confirmed by biopsy among women with ASC-H ranges from 26% to 68%. Rates of high-risk HPV DNA positivity are 40–51% among women with ASCUS, whereas they are 74–88% among women with ASC-H. Consequently, ASC-H should be considered to represent equivocal HSIL and a productive HPV infection. Thus, the performance of HPV testing allows for clear statements regarding the meaning of an ASC interpretation.

The 2001 revisions to the Bethesda System also eliminated the category of AGCUS (atypical glandular cells of undetermined significance) and identified three subcategories of atypical glandular cells (AGCs):

- AGC not otherwise specified
- AGC favoring neoplasia
- adenocarcinoma in situ (AIS)

**Table 6.2** The 2001 Bethesda System

Specimen adequacy
Satisfactory for evaluation (8000–12 000 well-visualized squamous cells for conventional smears and 5000 squamous cells for liquid-based preparations ( <i>note presence/absence of endocervical/transformation zone component</i> —there should be at least 10 well-preserved endocervical or squamous metaplastic cells)
Unsatisfactory for evaluation (specimens with >75% of epithelial cells obscured)

**Table 6.2** Continued

<b>General categorization</b>
Negative for intra-epithelial lesion or malignancy
Epithelial cell abnormality
Other
<b>Interpretation/result</b>
<b>Negative for intra-epithelial lesion or malignancy</b>
<ul style="list-style-type: none"> <li>• <b>Organisms</b> <ul style="list-style-type: none"> <li>– <i>Trichomonas vaginalis</i></li> <li>– Fungal organisms morphologically consistent with <i>Candida</i> species</li> <li>– Shift in flora suggestive of bacterial vaginosis</li> <li>– Bacteria morphologically consistent with <i>Actinomyces</i> species</li> <li>– Cellular changes consistent with herpes simplex virus</li> </ul> </li> </ul>
<ul style="list-style-type: none"> <li>• <b>Other non-neoplastic findings</b></li> </ul>
Reactive cellular changes associated with: <ul style="list-style-type: none"> <li>– inflammation (includes typical repair)</li> <li>– radiation</li> <li>– intrauterine contraceptive device</li> </ul>
Glandular cells status posthysterectomy
Atrophy
<b>Epithelial cell abnormalities</b>
<ul style="list-style-type: none"> <li>• <b>Squamous cell</b> <ul style="list-style-type: none"> <li>– Atypical squamous cells (ASC)</li> <li>– of undetermined significance (ASCUS)</li> <li>– cannot exclude HSIL (ASC-H) (5–10% of ASC cases overall)</li> </ul> </li> <li>• <b>Low-grade squamous intra-epithelial lesion (LSIL)</b> (generally a transient infection with HPV) encompassing: human papilloma virus/mild dysplasia/cervical intra-epithelial neoplasia (CIN) 1</li> <li>• <b>High-grade squamous intra-epithelial lesion (HSIL)</b> (more often associated with HPV persistence and higher risk of progression) encompassing: moderate and severe dysplasia, carcinoma in situ; CIN 2 and CIN 3</li> <li>• <b>Invasive squamous cell carcinoma</b></li> <li>• <b>Glandular cell</b></li> <li>• <b>Atypical glandular cells (AGC)</b> (<i>specify endocervical, endometrial, or glandular cells not otherwise specified</i>)</li> <li>• <b>Atypical glandular cells (AGC)</b> (<i>specify endocervical, endometrial, or glandular cells not otherwise specified</i>)</li> <li>• <b>Endocervical adenocarcinoma in situ (AIS)</b></li> <li>• <b>Invasive adenocarcinoma</b></li> </ul>
<b>Other</b>
Endometrial cells in a woman ≥40 years of age

Reproduced with permission from Salomon D et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2116.

## Types of Pap Smear, Their Sensitivity, and Screening Guidelines

There are two main types of Pap smear: a conventional Pap smear, and liquid-based Pap smear.

### Conventional Pap Smear

For a conventional Pap smear, the cell specimen on the collection instrument is spread across a glass slide and fixed to it by either spraying a fixative on the glass slide (Fig. 6.1) or placing it in a vial containing an ethanol fixative.

Ideally, samples for this type of a Pap smear should be obtained from three locations: (i) the endocervical canal (E), (ii) the exocervix (including the entire transformation zone) (C), and (iii) posterior vaginal pool (posterior fornix) (V). The samples can be smeared separately on three glass slides that are marked with the letters E, C, or V, respectively.


Some investigators, however, do not advocate collecting samples from the posterior vaginal pool. Nevertheless, for screening, all three samples can be smeared and mixed on one glass slide. The smear should be thick enough that it is not transparent.

Pap smears on a glass slide should be evaluated by a trained laboratory technician or cytopathologist, utilizing


a regular light microscope (Fig. 6.2). In 1997, the US Food and Drug Administration (FDA) approved two systems for routine use as quality control (rescreening) devices. Although studies have shown that these systems can catch problems not detected on a microscopic evaluation of Pap smears, such technical triumphs have been overshadowed by conflicting opinions about their cost-effectiveness and accuracy among cytopathology professionals, clinicians, patients, and device manufacturers.

### Liquid-Based, Thin-Layer (ThinPrep) Pap Smear


A ThinPrep Pap smear involves rinsing or dropping the collection instrument into a vial containing a liquid fixative (Fig. 6.3). The cells obtained are filtered, placed on a



**Fig. 6.1** The proper technique for obtaining a sample of cells for a Pap smear.



**Fig. 6.2** The normal Pap smear. Benign superficial squamous cells (arrows) and endocervical cells (white stars) can be visualized by light microscopy.



**Fig. 6.3** A liquid-based Pap smear requires the collection instrument to be inserted into a vial containing a liquid fixative.

## 12 Immediate and Postpartum Newborn Care

*Julieta E. Irman and Gustavo F. Leguizamón*

The neonatal period comprises the four weeks following delivery. During this phase, the newborn must rapidly adjust to its extrauterine life. To survive and achieve normal development, it must make major physiologic changes, including increased respiratory gas exchange, switching from fetal to neonatal circulation, and taking over its own thermoregulation. This chapter addresses these major physiologic changes involved in the newborn's transition to its extrauterine life. It also offers the basics of medical interventions commonly used to assist newborns throughout this critical transition.

**Postpartum:** A term used to describe something that occurs after childbirth, usually involving the mother.

**Tachypnea:** This refers to an excessively rapid respiratory rate, defined as greater than 20 breaths per minute.

**Transition:** The transition period is referred to as 6–12 hours after birth, when the baby goes through physiological adaptation to extrauterine life.

**Vaginal introitus:** This is the anatomical term for the vaginal opening.

### Definitions

**Apgar score:** The Apgar score provides an objective method of evaluating the physical condition of a newborn infant soon after delivery. The score takes into account the heart rate, respiratory effort, muscle tone, skin color, and response to a catheter in the nostril. Each of these objective signs can receive 0, 1, or 2 points, and each test is performed at 1 minute and 5 minutes after delivery. A common mnemonic is APGAR: **A**ppearance, **P**ulse, **G**rimace, **A**ctivity and **R**espiration.

**Hyperbilirubinemia:** This term refers to excess bilirubin in the blood, usually characterized by jaundice or yellowing of the eyes.

**Hyperthermia:** Abnormally high body temperature that occurs when the body's metabolic heat production or environmental heat load exceeds the normal heat loss capacity (or when heat loss is impaired).

**Hypothermia:** A dangerous lowering of body-core temperature, caused by losing heat faster than it is produced by the body.

### The Respiratory Transition

The alveoli of the fetus in utero are filled with fluid that must be cleared during the initial transitional period, so that the baby can breathe. In addition, to ensure effective pulmonary perfusion and to match perfusion to ventilation, the baby must be able to increase blood flow to the lungs.

During the last few weeks of pregnancy, there is a maturation and recruitment of sodium channels in the epithelial cells of the lungs in response to endogenous steroid and catecholamine surges that are triggered by the onset of labor. It is through these epithelial sodium channels that a significant part of the fluid in the fetus' lungs is purged. Liquid is also driven out of the fetus' lungs through the pulmonary epithelium into the vasculature as well as through the mechanical *squeeze* and Starling forces that occur during the process of labor and vaginal delivery.

Newborns sometimes have difficulty purging all the liquid from their lungs, particularly if they are late pre-term babies. As a result, they may exhibit respiratory difficulties that require stabilization and immediate supportive therapy, such as supplemental oxygen and assist-

ed ventilation. They are also at increased risk for associated morbidities.

Wang et al. estimated that nearly one-third of late preterm newborns exhibit respiratory difficulties. Neonates who are born by cesarean delivery before labor begins are at increased risk for respiratory distress, as are late preterm males compared with late preterm females. Hemodynamic instability caused by hypothermia or hypoglycemia may worsen the newborn's underlying respiratory distress.

Acute respiratory distress syndrome (RDS) is the most common respiratory condition experienced in newborns. The condition, which is characterized by severe difficulty in breathing and related complications, occurs primarily in neonates born between 34 and 36 weeks' gestation. It is the fourth leading cause of death for neonates in the United States (Fig. 12.1).


Late preterm infants also are at increased risk of having low Apgar scores, transient tachypnea of the newborn (TTN), persistent pulmonary hypertension, and respiratory failure. TTN and RDS are both common respiratory conditions in the late preterm newborn and are related to difficulty in clearing fluid from the lungs or a surfactant deficiency, or both. The protocols for managing a child in respiratory distress are covered later in this chapter.

## The Circulatory Transition

As described in Chapter 9, there is a substantial difference between the circulation of a fetus and a neonate. In the womb, well oxygenated blood from the placenta is delivered to the fetus through the umbilical vein. The umbilical vein gives off branches to the left lobe of the liver and then continues as the ductus venosus (Fig. 12.2). The left hepatic vein fuses with the well oxygenated ductus venosus and flows into the inferior vena cava to reach the left atrium by crossing thorough the foramen ovale. Then, via the aorta and carotid circulation, this blood supplies the brain and upper body. The right ventricular output is directed through the ductus arteriosus to the descending aorta.

Since the pulmonary vascular resistance is high and the mean pulmonary artery pressures are higher than aortic pressures, the flow is mainly directed toward the ductus arteriosus, leaving the pulmonary circulation with 5–10% of the ventricular output. Finally, fetal blood returns to the placenta through the umbilical arteries.

However, when delivery occurs, clamping the umbilical cord provokes a sudden decrease in the amount of neonatal blood draining toward and away from the baby. This leads to a sudden increase pressure in the systemic circulation and a decrease in the right side circulation, re-



**Fig. 12.1** Respiratory distress syndrome (RDS) is the fourth leading cause of death among neonates in the United States at approximately 6 per 100 000 live births. Adapted from the National Center for Health Statistics, 1999 period birth/infant death data; prepared by March of Dimes Perinatal Data Center, 2002

versing the right-to-left shunt and leading to the closure of the ductus arteriosus. Prostaglandins play a pivotal role in maintaining patency of the ductus arteriosus in utero and in its closure during early neonatal life.


## The Thermoregulatory Transition

Thermoregulation is a critical physiologic function that is closely related to the transition and survival of the infant. An understanding of transitional events and the physiologic adaptations that must be made is essential in helping the neonate to maintain its thermal stability. This section reviews neonatal thermal regulation, heat loss and gain, and infant thermoregulatory behavior. Measures to ensure thermal stability for the neonate are discussed later in this chapter.

### Neonatal Thermoregulation

Babies are not as adaptable as adults to temperature change. A baby's body surface is about three times greater than an adult's, relative to the weight of the body. Babies can lose heat rapidly, as much as four times more quickly than adults. Premature and low birth weight babies usually have little body fat and may be too immature to regulate their own temperature, even in a warm environment. Even full-term and healthy newborns may not be able to maintain their body temperature if the environment is too cold.






**Fig. 12.2** The fetus receives all the necessary nutrition, oxygen, and life support from the mother's placenta via the blood vessels in the umbilical cord. Waste products and carbon dioxide from the fetus are sent back through the umbilical cord and placenta to the mother's circulation to be eliminated.

When babies are stressed by cold, they use energy and oxygen to generate warmth. If skin temperature drops just one degree from the ideal 36.5 °C (97.7 °F), a baby's oxygen use can increase by 10%. Keeping babies at optimal temperatures, neither too hot nor too cold, enables them to conserve energy and build up reserves. This is especially important when babies are sick or premature.

For optimal thermal stability the baby's temperature must be kept within the Thermal Neutral Zone (**Fig. 12.3**). Once stabilized within the Thermal Neutral Zone, the baby's energy expenditure and oxygen consumption are minimized, promoting optimal growth.

Thermoregulation is controlled by the hypothalamus, a region of the central nervous system responsible for certain metabolic process and other activities of the autonomic nervous system. Thermal stimuli from the skin and body's deep (central) thermal receptors provide information on body temperature to the hypothalamus (**Fig. 12.4**). It is in the hypothalamus that sensory information describing thermal status throughout the body is processed and compared against the temperature set



**Fig. 12.3** Thermal stability is essential for every baby, especially those with limited metabolic capacity due to illness, prematurity, or low birth weight. Research has shown that the Thermal Neutral Zone for preterm babies less than 30 weeks old is less than 0.5 °C.

## 35 Pelvic Relaxation, Urinary Incontinence, and Urinary Tract Infection

Jon I. Einarsson

### Pelvic Relaxation

#### Incidence

Pelvic relaxation or pelvic organ prolapse is a common condition, with a recent study finding the prevalence of stage 2 and greater pelvic organ prolapse to be 37% in a population of 1004 women seeking care at a gynecologic clinic. While some of these women are asymptomatic, genital prolapse remains one of the most common reasons for gynecologic surgery in women after the fertile period.

#### Subtypes and Anatomy

Pelvic organ prolapse is often divided into three main subtypes, depending on where the prolapse is located (**Fig. 35.1**). In anterior prolapse (cystocele), the urinary bladder protrudes into the vagina. In posterior prolapse (rectocele), the rectum and/or the rectosigmoid protrudes into the vagina. Apical prolapse occurs when the cervix or the vaginal apex (following a hysterectomy) falls down through the vagina. Anterior and posterior prolapse are usually defects in the endopelvic fascia, which is a thick layer of connective tissue in the vagina, that is, the muscularis layer of the vaginal wall. This connective tissue can become detached from the normal attachments to the pelvic sidewall and/or become weakened or torn during childbirth or through wear and tear such as with chronic cough or constipation. Apical prolapse is more commonly associated with detachment or tearing of the uterosacral ligaments and the cardinal ligaments that connect to the pericervical ring to maintain the vaginal apex in a normal anatomic position.

#### Symptoms


Pelvic organ prolapse causes pelvic pressure, pain, painful intercourse and significantly impacts the quality of life of those who suffer from it. A cystocele can cause frequent urination or urinary retention, and a rectocele can cause difficulty in emptying the rectum during bowel movements.

#### Etiology

Several etiologic factors that contribute to pelvic organ prolapse have been identified such as higher age, increased parity, obesity, and heritability. Recent evidence also suggests that women with pelvic organ prolapse have smaller amounts of collagen in the fibrous connective tissue of the endopelvic fascia.

#### Diagnosis

Diagnosis is made during a detailed pelvic exam. It is important to distinguish between prolapse in different vaginal compartments, since surgical treatment varies. A standardized system to evaluate and report pelvic organ prolapse, called the POP-Q system, is widely used in research and clinical practice. Some consider this to be too complex and prefer a simpler system, such as the Baden-Walken halfway system. In this system, 1st degree prolapse extends halfway to the introitus, 2nd degree prolapse extends to the introitus, 3rd degree prolapse extends halfway outside the introitus and 4th degree prolapse means that there is complete eversion of the pelvic organs (procidentia).




**Fig. 35.1** Anatomy of the most common types of pelvic organ prolapse.

## Treatment

It is important to point out that asymptomatic pelvic organ prolapse usually does not require any therapy. Since conservative measures such as Kegel exercises or physical therapy do not seem to be effective, the main therapeutic option for symptomatic pelvic organ prolapse is reconstructive surgery, where defects in the endopelvic fascia are identified and repaired. While these surgical therapies can be effective, relapse rates of up to 50–60% have been reported. In order to reduce relapse rates, synthetic polypropylene mesh has been used to improve long-term success. While effective, synthetic mesh is costly and can cause erosions and, rarely, pelvic infections. The anterior and posterior compartment are usually repaired by re-approximating the endopelvic fascia with or without a mesh overlay. The “gold standard” treatment for apical prolapse is abdominal sacrocolpopexy with mesh (**Fig. 35.2**). Less invasive vaginal approaches such as the sacrospinous ligament fixation are especially applicable to older or less active patients. Recently, laparoscopic apical repairs have become more commonplace, thereby combining long-term durability and low morbidity.

These are especially applicable to younger active women, since sacrocolpopexy is associated with a lower rate of dyspareunia than the vaginal repairs.



**Fig. 35.2** Sacrocolpopexy involves attaching the vaginal apex to the promontory of the sacrum.

## Urinary Incontinence

### Incidence and Subtypes

Urinary incontinence, or involuntary leakage of urine, affects about 25% of premenopausal women and 40% of postmenopausal women.

The two most common types of urinary incontinence are stress incontinence and urge incontinence. Women who leak urine during coughing, sneezing, laughing, or lifting are considered to have stress urinary incontinence, and women who leak urine immediately following a strong urge to urinate have urge incontinence. Urge incontinence is also associated with frequent urination (more than 12 times during the day) and nocturia (urinating more than once at night). Some women have mixed urinary incontinence, with components of both stress and urge incontinence.

Overflow incontinence is a rare type of urinary incontinence, where women do not have normal bladder sensation or are unable to adequately empty the bladder. This leads to frequent urination, urinary leakage, and frequent urinary tract infections because urine stays in the urinary bladder at all times.

### Pathogenesis

If the urethral sphincter is weak, this can result in a subtype of stress urinary incontinence called intrinsic sphincter deficiency. The more common type is caused by too much mobility of the urethra (urethral hypermobility). The urethra is supported by connective tissue that can be weakened during childbirth, due to genetic defects in collagen or other connective tissue building blocks, or due to chronic cough or constipation. When the support of the urethra is weak or soft, the urethra sinks into the weakened connective tissue with increased intra-abdominal pressure, such as during cough or exercise. The pressure inside the bladder then becomes more than the pressure in the urethra leading to leakage of urine. This is similar to trying to stop a flow of water through a rubber hose by stepping on it. If the rubber hose is lying on soft grass, it is difficult to stop the flow of water by stepping on the hose, since the hose sinks into the grass and mud beneath it. However, if the hose is sitting on a hard surface, such as a sidewalk, it is much easier to stop the flow of water.

The causes of urge incontinence are more complex and often no specific cause is found. The most common cause is overactivity of the detrusor muscle of the bladder. The detrusor muscle is designed to be relaxed during bladder filling and only contract during bladder emptying. However, for a variety of reasons that are not fully un-

derstood, the bladder muscle sometimes becomes overactive, which leads to a strong urge to urinate. If the muscle contractions are very strong, this can lead to a sudden leakage of urine. Sometimes triggers can cause this, such as the sound of running water, but this may be completely unprovoked. The contractions of the bladder muscle are controlled by the autonomic nervous system. Therefore, women who have sustained an injury to the spine or have neurologic disorders such as multiple sclerosis and diabetes often have symptoms of urge incontinence.

### Diagnosis

A detailed history is the first step in diagnosing urinary incontinence, inquiring about duration of symptoms, medications, fluid intake, when the leaking occurs and how much this affects quality of life. A urinary diary can be helpful both for the patient and the physician. The patient notes frequency and amount of urination as well as frequency and amount of fluid intake. She will also be asked to note any urine leakage, if there was a strong sense of urgency prior to the leak and what she was doing when it happened. A simple, validated three-item questionnaire can also be useful to discern between urge and stress incontinence in clinical practice (**Fig. 35.3**).

Simple urodynamics can be performed in the doctor's office with minimal equipment. The patient first produces a urine sample to check for an infection. The post-void residual can then be measured by using ultrasonography or by inserting a narrow catheter into the bladder. Normally, the bladder should empty completely during urination, but a post-void residual greater than 100 mL is generally considered abnormal.

Next, the bladder is filled with water through the catheter to determine whether the bladder distends normally. Most women will feel that their bladder is filling with urine at 100–150 mL. When the bladder is filled up to about 300 mL, most women would go to the bathroom if socially convenient. The maximum capacity of the bladder is normally about 400–450 mL, which is associated with an extreme urgency. If the bladder starts to contract during the filling process, this is an indication of an overactive detrusor muscle. After filling the bladder with about 300 mL the catheter is removed and the patient is asked to stand up and cough or jump to see if there is any leakage, which would indicate a diagnosis of stress incontinence.

A more sophisticated way to measure the function of the urinary bladder is with so called multichannel urodynamics. During this test, narrow catheters are placed into the bladder and the vagina. Additionally, small electrodes are placed on the inner thigh to measure the contractions of the pelvic muscles. The bladder is slowly filled with water, but here the amount of water is more accurately measured and the results are automatically drawn on a strip of

# Index

**Notes:** Entries in *italics* refer to figures whilst those in **bold** refer to tables/boxed material.

## A

- abdominal bloating, pregnancy and 256, 258
- abdominal ectopic pregnancy 125
- abdominal examination 18, 18
- abdominal pain
- ectopic pregnancy 119
  - ovarian torsion 478
  - placental abruption 196
  - preterm labor 183
- abdominal surgery 364–365  
*see also* laparotomy
- abnormal labor *see* dystocia
- abortion
- spontaneous (miscarriage) *see* spontaneous abortion
  - therapeutic *see* therapeutic abortion
- abruptio placentae *see* placental abruption
- abscess(es)
- Bartholin gland 447, 447–448
  - breast 343
  - tubo-ovarian 313
  - vulval 449
- abstinence, contraception and 276
- acanthosis nigricans, vulval lesions 448
- accelerations (fetal heart rate) 91, 92, 93
- accessory breast tissue 344
- ACE inhibitors, contraindication in pregnancy 207–208
- achrochordons (skin tags), vulval 448
- acidemia, definition 91
- acidosis
- definition 91
  - fetal scalp pH 97
- acquired immunodeficiency syndrome *see* HIV infection/AIDS
- active phase (labor) 104, **104**, 104
- activin, follicular phase and 34
- acupuncture, dysmenorrhea treatment 401
- adenocarcinoma
- Bartholin gland 447–448
  - fallopian tube 483
- adenoma, breast 347
- adenomyosis 321–322
- adenosis, breast 346
- adnexal, definition 477
- adnexal masses 477–484
- evaluation 477–478
    - postmenopausal women 477–478, 479
    - premenopausal women 477, **478**
  - fallopian tubes 483
  - ovarian *see* ovary(ies), masses
  - tubo-ovarian abscess 313
  - see also specific types*
- adolescence
- breast tissue 344, 345
  - contraception 5–6
  - life-long patient care 4–5
  - pregnancy 5, 81
  - puberty *see* puberty
  - sexuality 492
- adoption 411
- adrenal gland
- fetal 78, 78
  - polycystic ovary syndrome and 388, 388–389
  - tumors, virilization and 395
  - see also specific hormones*
- adrenarche 4
- adverse outcomes 528
- definition 528
  - disclosure and discussing unintended outcomes 513, 529
  - documentation and prevention 531
  - informed consent and 529
  - risk management 530
  - three delays model 528, 528
  - see also specific outcomes*
- agenesis, definition 25
- AIDS *see* HIV infection/AIDS
- alcohol
- preconception care and pregnancy 82, **82**, 82
  - preterm birth/perinatal mortality and 235
- alcohol abuse questionnaire 82, **82**
- allergy, preterm labor/birth and 139
- allograft rejection, preterm labor/birth 139
- $\alpha$ -fetoprotein (AFP) 65, 66, 69
- multifetal pregnancy 174
- ambulatory pH monitoring 259, 259
- amenorrhea 378–386
- anovulatory cycles 404
  - breast-feeding and 343
  - definition 31
  - primary vs. secondary 378, 382
  - primary 378, 382–384
    - assessment/evaluation 382
    - diagnosis/treatment algorithm 382, 383
    - etiology 382, **382**
    - Turner syndrome and 382–384
  - secondary 378–382
    - diagnosis/treatment algorithm 379, 379
    - etiology 378–379, **380**
    - hypothalamic dysfunction 379–380
    - ovarian dysfunction 381
    - pituitary dysfunction 380–381
    - pregnancy *see* pregnancy
    - uterine dysfunction 382
    - see also specific causes*
- American Cancer Society, cervical cancer screening guidelines 61
- American College of Obstetrics and Gynecology (ACOG)
- Code of Ethics 519
  - limits of conscientious refusal 523
  - maternal autonomy vs. fetal beneficence 520
  - labor induction guidelines 234
  - lawsuit effects on OB/GYN practice 527, **527**
  - post-term pregnancy, fetal monitoring 267
  - testing recommendations in rhesus isoimmunization 162
- American Medical Association (AMA), Code of Ethics 517, 519, **519**
- communicable disease and 524
- American Society for Reproductive Medicine (ASRM), polycystic ovary syndrome criteria **387**, 387–388
- American Society of Colposcopy and Cervical Pathology (ASCCP), cervical cancer screening guidelines 61, **61**
- amitriptyline, chronic pelvic pain management 328
- amniocentesis 51, 69
- multifetal pregnancy 173, 174
  - PROM diagnosis 197
  - rhesus isoimmunization and 163, 163–164
  - spontaneous abortion and 129
- amnioinfusion 97
- amnionity
- definition 167
  - determination 168, 172, 172
- amniotic fluid 78
- bilirubin in 163, 163–164
  - fern-leaf pattern and PROM diagnosis 196, 196
  - fetal metabolic status and 97
  - volume
    - assessment in multifetal pregnancy 174
    - excess 167
    - post-term pregnancy 267
- Amsel's criteria, bacterial vaginosis 298–299
- androgen(s)
- follicular phase and 34
  - polycystic ovary syndrome and 388, 388–389, 391
  - Sertoli–Leydig cell tumors 483
  - sexual dysfunction management 492, **493**
  - Turner syndrome 384
  - see also specific hormones*
- anemia
- dysfunctional uterine bleeding 384

- hemolytic disease 161  
iron deficiency, postpartum  
outcomes 237
- anesthesia  
abnormal labor and 146–147  
multiple births 176  
therapeutic abortion and 286
- aneuploidy  
definition 43, 65, 167  
disorders 43–47  
monosomy 46–47  
polyploidy (trisomy) 43–46  
spontaneous abortion and 128, 128  
*see also specific disorders*  
fetal growth restriction and 182, 182  
screening tests *see* prenatal testing
- Angelman syndrome 50
- anger, domestic violence and 496
- angiogenesis  
cancer and 437–438  
luteal phase and 36
- anogenital warts 448, 454
- anorexia 9
- anovulatory cycles  
amenorrhea and 404  
dysfunctional uterine bleeding 384  
etiologies 407  
infertility 404, 407  
in PCOS 392–393, **393**, 407
- antenatal care *see* antepartum care
- antepartum care 85–89  
definition 81  
general recommendations 87, **88**  
glucose screening 86  
HIV infection and 224, **225**, **225**  
initial visit 86  
maternal mortality prevention 236  
multifetal pregnancies and 173–174  
nutritional support/weight  
management 87  
perinatal mortality prevention 236  
prenatal screening *see* prenatal  
testing  
repeat visits 86  
schedule 85  
serological tests 86  
ultrasonography 86  
vaccinations/prophylaxis 86–87
- antibiotics  
*Clostridium difficile* and 236  
GBS management 225–226, **226**  
maternal mortality prevention 238  
pelvic inflammatory disease 312, **312**  
preterm labor/birth  
management 142–143, 188  
PROM and 198, **200–201**  
puerperal endometritis 215  
syphilis management 229  
urinary tract infections 336  
*see also specific drugs*
- anticonvulsants, teratogenesis and **83**, 85
- antidepressant drugs  
breast-feeding and 247–248, **248**
- postpartum mood disorders 247  
pregnancy and 244–245  
adverse effects 244, 245, **245**  
contraindications/decision not to  
use 244  
discontinuation 244  
strategies for use 245  
*see also specific drugs/drug types*
- 'anti-dumping law' 531
- antihypertensive pharmacologic therapy  
breast-feeding and 208  
pregnancy and **156**, 207–208  
ACE inhibitor contraindica-  
tion 207–208  
indications for/goals 206–207  
pre-eclampsia–eclampsia syn-  
drome 155–156, **156**  
severe postpartum hypertension **208**  
*see also specific drugs*
- antiphospholipid syndrome, recurrent  
pregnancy loss 131
- antipsychotic drugs (neuroleptics)  
breast-feeding and 248  
pregnancy and 246
- antiviral drugs  
HIV infection/AIDS management 223, 224, **225**  
HSV management 223, **223**  
transmission reduction in discor-  
dant couples **309**  
*see also specific drugs/infections*
- anxiety disorders 9  
following sexual assault 497  
management 246  
menopause and 426  
pregnancy and 246, **246**  
symptoms 246
- Apgar score 110, **110**  
definition 107  
preterm infants 108
- aphthous ulcers, vulval 449
- apical prolapse 331
- ArginMax, sexual dysfunction manage-  
ment 492
- aromatase inhibitors  
infertility treatment in PCOS 393  
pelvic pain management 320
- arousal (sexual)  
disorders 490  
males vs. females 488
- arrest disorder, definition 145
- arterial embolization  
uterine atony management 216  
uterine leiomyoma management 7, 466, **468**
- ascites, definition 15
- Asherman syndrome, secondary amen-  
orrhea 382
- Asoprisnil, uterine leiomyoma manage-  
ment **468**
- asphyxia  
definition 91  
fetal heart rate and **98**
- assault, sexual *see* sexual assault
- assisted reproductive technology  
(ART) 409–410  
ethical issues 411  
indications 409–410  
key steps 409, 409  
male factor infertility 406, **412**  
multifetal pregnancies 168, 169, 410  
legislation and 170  
in PCOS 393  
*see also specific techniques*
- asthma  
definition 251  
pregnancy and  
chief complaints/examination 257  
diagnosis 252, 252  
epidemiology/prevalence 254  
etiology/pathogenesis and 255  
laboratory evaluation 259  
treatment and 260
- atrophic vaginitis 301
- atypical breast hyperplasia 346–347, **348**
- auscultation  
abdominal examination 18, 18  
definition 15  
intermittent, fetal surveillance  
and 96, 96
- autoimmune disorders 6  
*see also specific disorders*
- autonomy  
definition 518, **518**  
maternal  
fetal beneficence vs. 519–521  
nonmaleficence vs. 521–522
- Auto-Pap Screening System 20
- autosomal dominant disorders 49
- autosomal recessive disorders 49
- autosome, definition 41
- avidity index, definition 219
- B**
- 'baby blues' 247
- back pain  
definition 251  
pregnancy and  
chief complaints/examina-  
tion 257–258  
diagnosis 252, 253  
epidemiology/prevalence 254  
etiology/pathogenesis and 255  
laboratory evaluation 259  
prevention 260, **263**  
treatment 260, 260–261
- bacterial infections  
antibiotic therapy *see* antibiotics  
pregnancy and 225–229, 298  
GBS 225–229  
maternal mortality and 238  
premature labor and 142–143, 186, 198, 236  
sexually-transmitted  
non-ulcerative lesions 305–306  
ulcerative lesions 306–307, **308**, 308–309  
*see also specific infections/organisms*

- bacterial vaginosis (BV) **293**, 294, 298–300  
 clinical features/diagnosis 298–299  
 diagnostic criteria 298–299  
 laboratory evaluation 299, 299  
 Pap test and 299  
 vaginal discharge 298, 298  
 epidemiology 298  
 etiology/pathogenesis 298  
 pregnancy and 298  
 maternal mortality 238  
 premature labor and 186  
 treatment options 299–300  
 treatment 299–300  
 abortion/hysterectomy and 299  
 drugs used 299, **299**  
 symptomatic 299
- balanced translocations 48  
 barrier contraceptive methods 277  
 Bartholin glands 447, 447–448  
 Behçet disease, vulval lesions 449  
 beneficence  
 definition 518, **518**  
 fetal, maternal autonomy vs. 519–521  
 benzodiazepines 246  
 neonatal effects of exposure 246, **246**  
 PMS/PMDD management 418  
 beta-mimetic agents, as tocolytics **186**, 187  
 Bethesda cervical cancer classification system  
 2001 revision 58, **58**  
 Bethesda System, cervical cancer classification 57–58  
 bilirubin  
 amniotic fluid levels 163, 163–164  
 excessive *see* hyperbilirubinemia  
 bimanual examination 19  
 biometry, fetal growth restriction 185  
 biophysical profile (BPP)  
 fetal growth restriction 185  
 multifetal pregnancy and 174  
 post-term pregnancy 267  
 PROM management and 197–198  
 biopsies 20–21  
 breast mass evaluation 345, 354  
 cervix 20–21  
 endometrial *see* endometrial biopsy  
 lymph nodes in breast cancer 355, 355–356  
 vagina 21  
 vulva 21, 450  
*see also specific types/methods*
- bipolar disorder  
 breast-feeding and medications 248  
 pregnancy and 245
- BIRADS (Breast Imaging Report and Data System) 353–354, 354  
 birth *see* labor/delivery  
 birth control *see* family planning  
 bisphosphonates, menopause 428  
 bladder pain syndrome 326  
 bleeding  
 dysfunctional uterine *see* uterine bleeding, dysfunctional  
 sentinel bleeding 214  
 therapeutic abortion and 289  
 third trimester *see* third trimester bleeding  
*see also* hemorrhage; *specific types/causes*
- blighted ovum, definition 127  
 blood glucose monitoring, pregnancy 261  
 blood volume, multifetal pregnancies 170  
 body language, patient–provider communication 508, 509  
 body mass index (BMI)  
 polycystic ovary syndrome and 393  
 infertility 392  
 insulin resistance 389, 389  
 secondary amenorrhea and 379, 380  
 body temperature, ovulation and 404  
 ‘boggy’ uterus, adenomyosis and 321  
 bone density  
 breast cancer survivors and 357  
 menopause and 428  
 bony pelvis  
 anatomy 29–30, 100, **100**  
 labor mechanics and 100–101  
 measurement 100, 100–101  
 obstructed delivery and 237  
*see also entries beginning pelvic*
- borderline tumors 478  
 bowel hypersensitivity, dysmenorrhea 398  
 bradycardia, fetal 92  
 BRCA1/2 mutations 352, 437  
 breast cancer 352, 353  
 cancer prevention in carriers 352–353, **358**, 373, **438**, 481  
 ovarian cancer 437, **438**, 479, 481  
 breast(s) 341–350  
 accessory breast tissue 344  
 benign disease 345–348  
 abscess 343  
 adenoma 347  
 cancer risk and 345, 346, 347, **348**  
 carcinoma in situ 347  
 classification 345  
 fat necrosis 347, 348  
 galactoceles 343  
 lipoma 347  
 mastitis and inflammatory masses 343, 346, 347  
 nonproliferative 345–346  
 proliferative with atypia 345, 346–347, **348**  
 proliferative without atypia 345, 346  
*see also specific lesions*  
 cancer *see* breast cancer  
 density  
 age effects 345  
 HRT and 11, **11**  
 development 344, 345, 382  
 Turner syndrome and 383–384  
 examination 341–342, 353  
 lactation 341, 342  
 disorders associated 343  
*see also* breast-feeding masses 345  
 benign *see above*  
 biopsy 345, 354  
 imaging 345, 354, 354  
 malignant *see* breast cancer  
 nipple discharge 343, 344  
 pain (mastalgia) 344  
 structure 341, 341  
*see also* mammography
- breast cancer 351–360  
 diagnosis 354–355  
 epidemiology 351  
 etiology/pathophysiology 10, 351–352  
 cancer stem cells 438  
 genetic factors 352, 353  
 HRT and 10–11, 352, 429  
 oral contraceptives 352  
 pregnancy and 351, 357  
 reproductive hormones and 351–352, **357–358**  
 reproductive risk factors 351  
 lymph node involvement **355**, 355, 355–356  
 nipple discharge and 344  
 postmenopausal women 10–11, 351  
 prevention 352–353  
 bilateral mastectomy 353  
 exercise 351  
 hormonal 352–353, **358**  
 life-style modification 351  
 quantitative risk assessment tools 352  
 screening 353–354  
 breast examination 353  
 mammography 353–354, 354  
 MRI 354, 354  
 surgical staging 355  
 survival rates **355**  
 survivors, medical care 356–357  
 bone density and osteoporosis 357  
 fertility issues 356–357  
 HRT 357  
 treatment 355–356  
 adjunctive therapy 356  
 bone density and 357  
 factors affecting 355, **355**  
 fertility and 356–357  
 initial surgical treatment 355–356  
 locally advanced cancer 356  
 local therapy 355–356  
 radiotherapy 356  
*see also* mammography
- Breast Cancer Risk Assessment (BRCA) tool 352  
 breast cysts 345–346  
 breast-feeding 342  
 amenorrhea and 343  
 antidepressants and 247–248, **248**  
 antihypertensives and 208  
 antipsychotics/mood stabilizers 248  
 breast cancer reduction and 351  
 breast disorders associated 343

- contraception and 343–344  
 health benefits 342  
 HIV and 224, 342  
 maternal nutrition 9–10  
 neonatal care 112, **114**  
 sexuality/sexual dysfunction and 492  
 Breast Imaging Report and Data System (BIRADS) 353–354, 354  
 breast milk 341, 342  
*see also* breast-feeding  
 Burch procedure 335, 335
- C**
- CA-125, ovarian cancer diagnosis 477–478, 479  
 calcium channel blockers, as tocolytic agents 188  
 calcium supplements, PMS/PMDD management 418  
 canalization, definition 25  
 cancer 435–440  
 angiogenesis and 437–438  
 cellular characteristics/behavior 435, 435  
 epigenetics and 438  
 hormonal contraception and 279  
 immunology 438  
 multistep carcinogenesis 437  
 oncogenes 437  
 stem cells 438  
*see also* tumor(s); *specific malignancies*  
*Candida albicans* 296  
 candidiasis  
 vaginal overgrowth 296  
 vulvovaginal *see* vulvovaginal candidiasis  
 cannabis, preterm birth/perinatal mortality and 235  
 carbohydrate metabolism, pregnancy-related changes 75, **78–79**, 86  
 carcinoma in situ, breast 347  
 cardiac output, multifetal pregnancies and 170  
 cardiometer 92  
 cardiovascular system  
 fetal circulation 77–78  
*see also* fetal heart rate (FHR)  
 hormonal contraceptives and 279  
 maternal changes during pregnancy 75, 75–76  
 multifetal pregnancies and 170  
 menopause and 11, 429  
 neonatal transition 108, 109  
 Carnett's test 327  
 carriers, genetic disorders 49  
 cell nucleus, definition 41  
 cephalopelvic disproportion (CPD), dystocia and 147  
 certification 528  
 cervical cancer 457–459  
 classification/terminology **57**, 57–58, **58**, 453  
 detection rates and 61, **61**  
 colposcopy 20–21  
 epidemiology 57, 459  
 etiology/pathogenesis  
 hormonal contraception and 279  
 HPV and *see* human papilloma virus (HPV)  
 FIGO staging **454**, 457, 458, **459**  
 global burden 459  
 histological appearance 60  
 premalignant lesion *see* cervical neoplasia  
 prevention  
 screening *see* cervical screening  
 vaccination 4–5, 455, **459–460**  
 survival **459**  
 treatment 62, 457–458  
 cervical dilatation, therapeutic abortion and 286  
 cervical fluid, PROM diagnosis 196  
 cervical insufficiency  
 definition 135  
 preterm labor/birth 139  
 spontaneous abortion 131  
 cervical laceration, therapeutic abortion and 289  
 cervical length (CL), preterm labor and 141, 142, **142**, 145, 185  
 PROM and 192, 192  
 cervical neoplasia 453–457  
 classification/nomenclature 453, 453, **454**  
 diagnosis 456  
 HPV and pathogenesis *see* human papilloma virus (HPV)  
 as premalignant lesion 453  
 prevention  
 screening *see* cervical screening  
 vaccination 455, **459–460**  
 regression 457  
 treatment 457  
 cervical ripening  
 definition 135  
 induction methods 268, 268–269  
 therapeutic abortion and 287, 287  
 cervical screening 57–64, 455–456  
 alternative approaches in developing countries 459  
 cervical–vaginal cytology 455  
 Pap smear *see* Pap smear  
 combined test 456, **456**  
 direct visual inspection 456  
 effectiveness 57  
 guidelines 61, **61**  
 HPV DNA testing 61–62, 455–456  
 cervicography, cervical screening and 456  
 cervicostomy, cervical screening and 456  
 cervicovaginal secretions, definition 135  
 cervix 28  
 biopsy 20–21  
 displacement in endometriosis 316, 316, 399, 399  
 ectopic pregnancy 125  
 incompetence *see* cervical insufficiency  
 injury  
 abortion and 289  
 infertility and 408  
 long-term outcomes 457  
 lesions 453–460  
 cancer *see* cervical cancer  
 diagnosis 456  
 neoplasia *see* cervical neoplasia  
 preservation during  
 hysterectomy 367, **375**  
 speculum examination 19  
 vaginitis diagnosis 295  
 punctate hemorrhages 300  
*see also* entries beginning *cervico-/cervical*  
 cesarean delivery  
 multiple births 177  
 obstructed births 237  
 third trimester bleeding and 199  
 chancroid 308, **308**  
 chemical contraceptive methods 277  
 chemical pregnancy, definition 127  
 chemoradiotherapy, cervical cancer therapy 457–458  
 chemotherapy  
 breast cancer 356  
 endometrial cancer 474, **475**  
 malignant molar pregnancies 444  
 ovarian cancer 480  
 primary ovarian failure 423  
 children  
 breast tissue 344  
 domestic violence 496  
 Chlamydial cervicitis 306, 306  
 hormonal contraception and 279  
 Chlamydial infections 306, 306, 308  
 infertility and 406  
 prophylactic treatment following sexual assault 497  
*see also* *specific conditions*  
*Chlamydia trachomatis* 306, 308  
 cholecystitis  
 definition 251  
 pregnancy and  
 chief complaints/examination 258  
 diagnosis 252–253, 253  
 epidemiology/prevalence 254  
 etiology/pathogenesis and 255  
 laboratory evaluation 259  
 treatment 261  
 cholestasis  
 definition 251  
 pregnancy and  
 chief complaints/examination 258  
 diagnosis 252  
 epidemiology/prevalence 254  
 etiology/pathogenesis and 255  
 laboratory evaluation 259  
 treatment 261  
 chorioamnionitis, maternal mortality and 238  
 choriocarcinoma 443  
 chorionicity 172



- definition 167  
determination 168, 168, 171–172, 173  
fetal gender and 172  
intertwin membrane 172–173  
membrane origin 173  
number of placental masses and 172
- chorionic villus sampling (CVS) 51, 68  
multifetal pregnancy 173, 174  
spontaneous abortion and 129
- chromosome(s) 42–43  
abnormalities *see* chromosome abnormalities  
definition 41  
X-chromosome disorders *see* X-chromosome disorders  
chromosome abnormalities 43–50  
fetal growth restriction and 182, 182  
numerical 43–47, 128, 128  
*see also* aneuploidy  
prenatal detection *see* prenatal testing  
spontaneous abortion and 128  
structural 47–49  
*see also specific abnormalities/disorders*
- chromosome deletions 47  
chromosome duplications 47  
chromosome translocation(s) 43, 48  
definition 42  
mechanisms 47–48  
*see also specific types*
- chronic hypertension, in pregnancy *see* under hypertension, in pregnancy
- chronic illness  
management, medical economics and 503  
sexuality/sexual dysfunction and 492
- chronic pelvic pain *see* pelvic pain
- climacteric *see* perimenopause
- clinical ethics *see* ethical issues
- cliterydymia 490
- clomiphene, anovulatory infertility treatment in PCOS 392, **395**
- Clostridium difficile*, clindamycin use and 236
- cocaine, uterine rupture risk 194
- cognition, menopause and 426
- cognitive behavioral therapy (CBT), female sexual dysfunction and 491
- cold stress, neonates 108–109
- colposcope 20
- colposcopy 20, 20–21, 456  
sexual assault 497
- combination pill 278, **278**  
dysmenorrhea treatment 401, **402**  
hirsutism management 394  
menopausal hot flushes and 427  
pelvic pain and endometriosis management 318–319  
PMS/PMDD management 418  
polycystic ovary syndrome and 392
- communication 507–516  
core values (physician) 507, **507**
- patient-provider 508–513  
body language and 508, 509  
cross-cultural interactions 513–514  
delivering information to patient 510–511, **510–511**  
difficult patients 515  
disclosing medical errors 513  
eliciting information at interview 508–510  
*see also* history taking  
empathy 512  
giving bad/difficult news 511–513, **512**  
importance of 508  
interpreters and 514, **514**  
litigation prevention and 528, 530  
patient literacy and 511  
patients with limited language skills 514  
research subjects and 515  
terminating relationship 515  
physician-physician 515–516
- complement system, preterm labor/birth 139
- completed abortion, definition 127
- conceptus, definition 41
- condoms 277
- condylomas 309, 448, 454  
*see also specific types/causes*
- condylomata acuminata 448  
diagnosis 456
- congenital abnormalities  
chromosomal etiology *see* chromosomal abnormalities  
fetal growth restriction and 182, 185  
spontaneous abortion and 129
- congenital cytomegalovirus (CMV) 220, **221, 231**
- congenital syphilis 228, **228**, 307
- congenital toxoplasmosis 230–231  
clinical manifestations **231**  
management 230  
prevention 230, **230**
- conization 457
- conjugated equine estrogen (Premarin) **430**
- consent, informed 510–511, **510–511**, 529
- constipation, pregnancy and 256, 258, 262
- contingent sequential testing 68
- continuous electronic fetal heart rate monitoring 96–97
- contraception 5–6, 275–284  
breast-feeding and 343–344  
compliance 275  
emergency 281–282, 497  
ethical dilemmas 523–524  
following sexual assault 497  
medical factors 275–276  
contraindications 275, **276**, 279  
methods 276–280  
barrier 277  
behavioral 276
- hormonal *see* hormonal contraceptive methods  
IUDs *see* intrauterine device (IUD)  
*see also specific methods*  
patient issues 275–276  
social/cultural factors 275  
WHO guidelines 5, **6**
- contraceptive sponge 277
- contractility, definition 135
- contractions (uterine) *see* uterine contractions
- contraction stress test (CST), post-term pregnancy 267, 267
- convulsions  
anticonvulsants and teratogenesis **83**, 85  
eclamptic 149, 150, 155
- cordicentesis, rhesus isoimmunization diagnosis 163, 163
- cornual (interstitial) pregnancy 124, **125**
- corpus luteum 36, 36, 37
- corticosteroids, lung maturation *see* steroid-induced lung maturation
- corticotropin-releasing hormone (CRH), preterm labor/birth and 139–140, **148**
- credentialing 528
- Crohn disease, vulval lesions 449
- cultural factors  
contraception and 275  
patient-provider communication 513–514
- curettes 21, 21
- cyst(s)  
Bartholin gland 447, 447–448  
breast 345–346  
fallopian tubes 483  
mesosalpingeal cysts 483  
ovary *see* ovarian cysts  
vaginal wall 448
- cystocele (anterior prolapse) 331, 332
- cystoscopy, urinary incontinence diagnosis 334
- cytomegalovirus (CMV)  
clinical features associated 220, 220  
infection rates/epidemiology 220  
pregnancy and 220–222  
diagnosis of maternal/fetal infection 220, 221  
neonatal sequelae 220, **221, 231**  
prevention 220, 222  
screening 222
- cytoplasm, definition 41

## D

- danazol, pelvic pain management 320
- decelerations (fetal heart rate) *see* fetal heart rate (FHR), decelerations
- depression 8–9  
diagnostic criteria 243, **243**  
epidemiology 243  
following sexual assault 497  
menopause and 426

- postpartum *see* postpartum depression
- during pregnancy *see* depression, pregnancy and
- depression, pregnancy and 9, 243–245
- impact on fetus 242, 244, **244**
- impact on neonate/infant 244, **249**
- incidence 243
- risk factors 243, **243**
- treatment options 243–245
- decision not to medicate 244
- medication *see* antidepressant drugs
- non-pharmacological 246, 248
- dermatosis, vulvar 302
- descent (fetal) 101, 103
- desire disorders 489–490
- diabetes mellitus
- definitions 251
- pregnancy and
- chief complaints/examination 258
- diagnosis 253
- epidemiology/prevalence 254
- etiology/pathogenesis and 255
- gestational diabetes *see* gestational diabetes
- management 261
- preconception care and 84–85
- preterm birth/perinatal mortality and 236
- spontaneous abortion and 129
- type 1 251, 255
- type 2 251, 254, 255
- diaphragm, contraceptive 277
- dietary interventions
- dysmenorrhea treatment 400
- infertility and 409
- premenstrual syndrome treatment 418
- see also* nutrition
- dilation (dilatation) and curettage (D&C) 21, 374
- complications/risks 374
- ectopic pregnancy and 121–122, 122
- molar pregnancy, hydatidiform mole 442, 443
- as office procedure 374
- spontaneous abortion management 130
- therapeutic abortion 286
- dilation (dilatation) and evacuation (D&E) 287
- dilation (dilatation) and extraction (D&X) 288
- dimeric inhibin A 65
- dizygotic siblings
- definition 167
- twin birth rate 168
- DNA (deoxyribonucleic acid) 42
- definition 41
- fetal in maternal blood 52
- methylation, cancer and 438
- microarray chips, prenatal testing 53, 54
- repair genes, cancer and 436, 437, 472
- see also* chromosome(s); genetics/genomics
- domestic violence 495, 495–496
- dominant traits/disorders 49
- donovanosis 308–309
- Doppler ultrasonography 23
- fetal growth restriction
- assessment 185–186, 186
- management options and 188–189
- fetal surveillance 96
- rhesus immunization
- diagnosis 159, 160, **164–165**
- Down syndrome *see* trisomy 21 (Down syndrome)
- drospirenone, PMS/PMDD treatment **419**
- drug(s)
- illegal/abuse
- pregnancy and, maternal autonomy vs. fetal beneficence 520
- preterm birth/perinatal mortality and 235
- uterine rupture risk 194
- medical economics and 502
- preconception care and
- pregnancy 82, **83**
- spontaneous abortion and 129
- see also specific drugs/drug types*
- ductal epithelial hyperplasia 346
- ductus arteriosus, closure 108
- due date calculation 265, 265
- duty of care 530
- dyschezia, endometriosis 316
- dysgerminomas 481–482
- dyslipidemia, polycystic ovary syndrome and 391
- dysmenorrhea 397–402
- definitions 397
- diagnosis/assessment 397
- history/chief complaint 398–399
- laboratory evaluations 399
- physical assessment 399, 399
- severity scoring 398, **398**
- endometriosis 316, 399
- epidemiology/prevalence 397
- etiology/pathophysiology 398
- onset 397, **397**
- primary 397, 399
- secondary 397
- treatment 399–401
- combined contraceptive pill 401, **402**
- failure 402
- levonorgestrel-releasing intrauterine system 401
- nifedipine 401
- nonpharmacological 400, 401
- NSAIDs 400, **400**
- unproven 401
- dyspareunia 490
- endometriosis 316
- dystocia 145–148
- definitions 135, **145**, 145–146
- diagnosis 146
- epidemiology/prevalence 146
- etiology/pathophysiology 146–147
- cephalopelvic disproportion 147
- hypocontractile uterus 146
- neuraxial anesthesia 146–147
- persistent occiputoposterior position 147
- post-term delivery 266, 266, 269
- risk factors 146, **146**
- first stage **145**, 146
- management 147–148
- first stage 147
- second stage 147–148
- second stage **145**, 146
- E**
- eating disorders 9
- eclampsia *see* pre-eclampsia–eclampsia syndrome
- ectopic pregnancy 119–126
- definition 15, 119
- diagnosis 119, 120–122
- D & C 121–122, 122
- HCG levels 119, 121, 123
- heterotopic pregnancy and 124
- physical examination 120
- serum progesterone 121
- ultrasonography 119, 121, 121
- etiology/pathophysiology 119–120, **120**, 125
- history 120–122
- maternal mortality 122, 125
- prevalence 119
- sites 119, 120, 124
- symptoms/signs 119, 120
- treatment options 122–125
- expectant management 124
- heterotopic pregnancy and 124
- medical 122–123, 123, **124**
- nontubal pregnancy 124–125, **125**
- surgical 122
- see also specific methods*
- Edinburgh Postnatal Depression Scale 247
- Edwards syndrome (trisomy 18) 45, 45
- electronic health records
- medical economics and 502
- preventing harm and 531
- embryogenesis, genital *see* genital embryogenesis
- embryonal carcinoma 482
- emergency contraception 281–282
- following sexual assault 497
- Emergency Treatment and Active labor Act (EMTALA) (1986) 531–532
- empathy, patient–provider communication 512
- empty sella syndrome, secondary amenorrhea 381
- endocervical curettage 21, 21
- endocrine system
- disorders 6
- pregnancy related changes 6, 75

- preterm labor/birth and 139–140, **148**, 236  
 spontaneous abortion and 129  
*see also specific disorders*  
 fetal endocrinology 78, 78  
*see also specific systems/hormones*  
 endodermal sinus tumor 482  
 end-of-life, medical economic issues 503  
 endometrial biopsy 21, 22, 374–375  
 cancer detection/diagnosis 472–473, **473**  
 infertility diagnosis/evaluation 405  
 polycystic ovary syndrome and 394  
 endometrial cancer 471–476  
 definition 471  
 diagnosis 471, 472–473  
 biopsy 472–473, **473**  
 history/chief complaint 472  
 physical examination 472  
 epidemiology 471, 472  
 FIGO staging system 473, **473**  
 follow-up 474  
 management  
 adjuvant treatments 474, **475**  
 surgical staging/treatment 473–474  
 ovarian cancer and 474  
 pathology/pathogenesis 436, 471, 471, 472  
 Lynch syndrome and 436, 473  
 premalignant lesion 471  
 prevention 472  
 recurrent disease 474  
 screening 473  
 type I endometrioid 471  
 PTEN and 436, 472  
 type II 471  
 p53 link 472  
 endometrial hyperplasia 471  
 polycystic ovary syndrome and 394  
 endometriomas 317–318, 373  
 endometriosis 6–7, 315–321  
 definition 15, 315  
 diagnosis/clinical features 7, 317  
 dysmenorrhea and 399  
 history/symptoms 6–7, 316, 317  
 laboratory evaluations 317  
 pelvic pain *see* pelvic pain  
 physical examination 316, 316, 399, 399  
 surgical 317  
 differential diagnosis 317  
 epidemiology/prevalence 6, 315, 315  
 etiology/pathophysiology 315–316  
 common locations 317  
 ovarian cysts and 316, 317–318  
 infertility and 7, 318, 408  
 staging 317, 318  
 treatment 7, 8, 317–321, 408  
 endometriomas 317–318  
 hormonal 318–321, **319**, **320**  
 infertility management 318, 319  
 pelvic pain *see* pelvic pain  
 surgical 321, **322**, **323**
- endometritis, therapeutic abortion and 288  
 endometrium  
 cancer *see* endometrial cancer  
 endometriosis *see* endometriosis  
 menstrual cycle changes 436  
 therapeutic abortion and infection 288  
*see also entries beginning endometrio-/endometrial*  
 engagement (fetal) 101, 103  
 environmental factors  
 fetal growth restriction and 182–183  
 primary ovarian failure 423  
 spontaneous abortion and 129  
*see also specific factors*  
 epidural anesthesia  
 abnormal labor and 146–147  
 multifetal pregnancy/birth 176  
 epigastric pain, pre-eclampsia–eclampsia syndrome 152  
 epigenetics 50  
 cancer and 438  
 epilepsy  
 anticonvulsants and teratogenesis **83**, 85  
 preconception care and 85  
*see also convulsions*  
 episiotomy 105, 105  
 best evidence **106**  
 external genitalia anatomy and 28, 28  
 epithelial breast hyperplasia 347  
*Escherichia coli*, urinary tract infections 336  
 estradiol  
 breast cancer and **357–358**  
 menopausal symptoms and 425  
 vaginal, dryness therapy 491  
 estrogen(s)  
 atrophic vaginitis 301  
 bone effects 12  
 breast cancer and 351–352, **357–358**  
 endometrial cancer and 436  
 endometriosis and 315, 316  
 follicular phase and 34, 35  
 menopausal hot flushes and 427  
 ovulation and 36  
 preterm labor/birth and 140  
 sexual dysfunction management 491  
 Turner syndrome and 383  
 vaginal flora/physiology and 294  
*see also specific hormones*  
 estrogen–progestin contraceptives *see* combination pill  
 ethical issues 517–526  
 AMA Code of Ethics 517, 519, **519**  
 decision making guidelines 524–525, **525**  
 fetal reduction 175  
 fetus as patient 519–522  
 maternal autonomy vs. fetal beneficence 519–521  
 maternal autonomy vs. nonmaleficence 521–522
- viability and 520  
 gender selection and 521  
 gynecological dilemmas 522–525  
 communicable disease 524  
 contraception in minors/non-competent individuals 523–524  
 therapeutic abortion 285, 522  
 HIV testing and results 520, 524  
 infertility 411  
 medical education and 517, 522  
 medical errors and 513  
 negative vs. positive patient rights 521  
 neonate as patient 522  
 principles of medical ethics 517–519, **518**  
 autonomy 518  
 beneficence 518  
 justice 519  
 nonmaleficence 518  
 'principlism' 517  
 third party rights 524  
*see also legal issues*  
 ethnicity/race  
 chronic hypertension and 205  
 health issues and 3, 3  
 maternal mortality and 234, 235  
 menopausal symptoms and 425  
 European Society of Human Reproduction and Embryology (ESHRE), polycystic ovary syndrome criteria **387**, 387–388  
 evidence-based medicine, medical economics and 502  
 examination(s) 15–24  
 definitions 15–16  
 history *see* history taking  
 imaging *see* imaging  
 laboratory tests *see* laboratory evaluation(s)  
 physical *see* physical examination  
*see also specific aspects; specific conditions*  
 exercise, birth to adolescence 5  
 expulsion (fetal) 103, 104  
 extension (fetal) 101, 103  
 external genitalia  
 anatomy 28, 28  
 definition 25  
 embryogenesis 25, 26  
 episiotomy and 28, 28  
 inspection 18  
*see also specific structures*  
 external rotation (fetal) 101, 103  
 eye infection, neonatal prophylaxis 112
- F**  
 fallopian tube(s)  
 anatomy 29, 29  
 common developmental abnormalities **25**  
 masses 484  
 cancer 483  
 cysts 483

- tubo-ovarian abscess 313  
*see also* adnexal masses  
 pregnancy in (tubal pregnancy) *see*  
 ectopic pregnancy
- family planning 275–284  
 contraception *see* contraception  
 medical economics and 501  
 psychiatric disorders and 241  
 sterilization 280, 280–281  
*see also* therapeutic abortion; *specific methods*
- fat necrosis, breast 347, 348
- female condoms 277
- female orgasm disorder (FAD) 490
- female sexual arousal disorder (FSAD) 490
- fertility  
 definition 403  
 life-style effects on 409  
*see also* infertility
- fertilization 37–38, 403, 403  
 site 37, 37  
 sperm penetration of ovum 37, 38  
 zygote formation 37, 38
- fetal alcohol syndrome 82, 82
- fetal attitude, labor/delivery and 101
- fetal blood  
 direct sampling 51, 52, 69  
 congenital syphilis detection 228  
 rhesus isoimmunization and 163  
 extraction from maternal  
 circulation 51–52  
 transfusion, rhesus  
 isoimmunization 163, 163, 164
- fetal cells, from cervix 52
- fetal circulation 77–78
- fetal distress  
 monitoring *see* fetal surveillance  
 uterine rupture and 196
- fetal DNA, in maternal blood 52
- fetal fibronectin (fFN), preterm labor/  
 birth diagnosis 141–142, 179, **189**
- fetal growth restriction (FGR) 180–181  
 asymmetric 181  
 common abnormalities 181  
 definition 180–181  
 diagnosis 181  
 history/chief complaint 184  
 physical examination 185–186  
 ultrasonography and 185–186,  
 186, 188–189  
 epidemiology/prevalence 181  
 etiology/pathophysiology 180–181,  
 182–183, **183**  
 aneuploidy 182, 182  
 congenital anomalies 182, 185  
 environmental/life-style fac-  
 tors 182–183  
 multiple gestations 182  
 nutritional deficiency 182  
 management 188–189  
 algorithm 189  
 perinatal mortality 180–181  
 prenatal screening 181  
 symmetric 181, 188
- fetal heart beats  
 multifetal pregnancy diagnosis/  
 assessment 171–172  
 rate measurement *see* fetal heart rate  
 (FHR)
- fetal heart rate (FHR) 92–96  
 accelerations 91  
 transient (normal) 92, 93  
 asphyxia/hypoxia relationship 95, 95,  
 96, **98**  
 continuous electronic  
 monitoring 96–97  
 decelerations 91  
 early 92, 94  
 late 94, 95  
 severity classification 94  
 transient (normal) 92, 94–95  
 variable 94, 94–95  
 decreased variability 92, 93  
 definitions 91  
 interventions for altered FHR 97–98  
 clinical 97–98  
 operative 98  
 multiple births 176  
 normal variations 92, 92  
 post-term fetus 267  
 sinusoidal pattern 95–96  
 as surveillance tool 91
- fetal lie, labor/delivery and 101
- fetal position, labor/delivery and 101,  
 102  
 malposition, dystocia and 147
- fetal presentation, labor/delivery  
 and 101  
 multifetal pregnancy/birth 176–177,  
 177
- fetal pulse oximetry 97
- fetal reduction 175, **178**
- fetal size  
 labor/delivery and 101  
 post-term babies 266  
 restricted growth *see* fetal growth  
 restriction (FGR)
- fetal station, labor/delivery and 101, 102
- fetal surveillance 91–98  
 bradycardia 92  
 definitions 91  
 Doppler ultrasonography 96  
 fetal growth restriction and 185  
 heart rate *see* fetal heart rate (FHR)  
 intermittent auscultation 96, 96  
 interventions 97–98  
 maternal vital signs and 91, 97  
 metabolic status assessment 97  
 multiple births 176  
 post-term pregnancy 267, 269  
 tachycardia 92
- fetus  
 ethical issues concerning *see under*  
 ethical issues  
 growth potential of 179  
 growth restrictions/low birth  
 weight 179–190  
 consequences 179, 179  
 epidemiology/prevalence 181
- growth restriction *see* fetal growth  
 restriction (FGR)  
 mortality/morbidity and 179  
 preterm birth and *see* preterm la-  
 bor/birth  
*see also* low birth weight; preterm/  
 premature babies  
 hypoxia/acidosis risks 91  
 labor/delivery and *see* labor/delivery  
 maternal psychiatric disease  
 and 242, 244, **244**  
 multifetal pregnancy  
 pathophysiology 170, 170–171, 174  
 physiology *see* maternal–fetal  
 physiology  
 post-term delivery and 266, 266, 268,  
 269  
 respiratory system 107  
 rhesus antigen zygosity  
 assessment 159  
 rhesus isoimmunization and *see*  
 rhesus isoimmunization  
 surveillance *see* fetal surveillance  
 viability, ethical considerations 520  
*see also* entries *beginning fet/o-/fetal*;  
 pregnancy
- fibroadenoma, breast 346
- fibrocystic breast disease 346
- fibroids (uterine) *see* uterine leiomyo-  
 mas
- fibromas  
 ovarian 482–483  
 uterine *see* uterine leiomyomas
- fibromyalgia, pelvic pain 326
- FIGO *see* International Federation of Gy-  
 necology and Obstetrics (FIGO)
- first trimester abortion 286–287, **287**
- first trimester screening (FTS) 50–51,  
 66  
 second trimester screening vs. 67, 67  
*see also* *specific methods*
- fissures, vulval lesions 449
- flexion (fetal) 101, 103
- fluconazole, vulvovaginal candidi-  
 asis 298
- fluorescence in situ hybridization  
 (FISH), prenatal testing 52–53, 53
- folic acid, preconception care 85, **89**
- follicle-stimulating hormone (FSH)  
 follicular phase of menstrual  
 cycle 32, 33, 34, 34  
 infertility treatment  
 ovarian hyperstimulation syn-  
 drome 410  
 in PCOS 393  
 oocyte pool analysis 404  
 perimenopause and 423, **424**, 426
- follicular atresia, definition 31
- follicular phase (menstrual cycle) 32,  
 32–35  
 average length of 32  
 follicle development during 32, 33  
 dominant follicle 34, 34  
 preantral follicles 33–35  
 preovulatory follicle 35, 35

- primary follicles 32
  - primordial follicles 33, 33
  - 'two-cell, two-gonadotropin theory' 33–34, 34
  - termination of 34, 34
  - follicle-stimulating hormone, follicular phase and 34
  - forceps delivery 105, 106
  - forensic examination, sexual
    - assault 497
  - fragile X syndrome 50, 426
  - fraternal dizygotic siblings,
    - definition 167
  - fundal height
    - fetal growth restriction
      - assessment 185
    - pre-eclampsia and 152
- G**
- gabapentin, chronic pelvic pain management 328
  - galactocele 343
  - galactorrhea 344
  - galactosemia, primary ovarian failure 423
  - gamete(s)
    - definition 31, 41
    - fusion (fertilization) 37
  - gametocyte, definition 31
  - gastroesophageal reflux disease, pregnancy and
    - chief complaints/examination 258
    - etiology/pathogenesis and 256, 256–257
    - laboratory evaluation/monitoring 259, 259
    - management 262
  - gastrointestinal disorders
    - pelvic pain and **325**, 326
    - pregnancy and
      - chief complaints/examination 258
      - diagnosis 253–254
      - epidemiology/prevalence 254
      - etiology/pathogenesis and 255–257, 256
      - laboratory evaluation 259–260
      - management 261–262
      - see also specific disorders*
  - gastrointestinal motility disorders
    - definition 251
    - see also specific disorders*
  - gender testing, ethical issues 522
  - gene, definition 41–42
  - gene expression, definition 42
  - generalized anxiety disorder (GAD) 246
  - generic medicines, medical economics and 502
  - genetic anticipation
    - autosomal dominant disorders 49
    - trinucleotide repeat disorders 49–50
  - genetics/genomics 41–56
    - basic concepts 42–43
    - cancer
      - breast cancer 352, 353
      - gynecological cancers 436, 472
    - chromosomes *see* chromosome(s)
  - definitions 41–42
  - diagnosis/management of genetic disorders 50–54
    - prenatal testing *see* prenatal testing
  - endometriosis and 315
  - impact on OB/GYN practice 42
  - Mendelian disorders 49
  - multifetal pregnancies and 169
  - non-Mendelian disorders 49–50
  - polygenic/multifactorial disorders 49
  - psychiatric disorders 242
  - see also individual genes; specific conditions*
  - genital embryogenesis 25–27, 26
    - abnormalities 25, **25**, 27
    - definitions 25
  - genital herpes *see* herpes simplex virus (HSV)
  - genitalia 28–30
    - embryological development *see* genital embryogenesis
    - external *see* external genitalia
    - internal 25, 26
    - see also specific structures*
  - genital ridge 25
  - genital tubercle 25, 26
  - genome, definition 42
  - genotype, definition 42
  - germ cell tumors **481**, 481–482
  - gestational age
    - determination 137
    - FGR diagnosis and 181, 185
    - infant mortality relationship 136
    - post-term pregnancy diagnosis 265
  - gestational diabetes 75, 251
    - diagnosis 253, **254**
    - epidemiology/prevalence 254
  - gestational hypertension
    - definition 203–204
    - diagnosis 204
    - pre-eclampsia and 204
    - prognosis 208
    - severe 204
    - treatment 207–208
      - non-pharmacological 207
      - pharmacological therapy *see* antihypertensive pharmacologic therapy
      - see also* pre-eclampsia–eclampsia syndrome
  - gestational trophoblastic diseases (GTDs) *see* molar pregnancy
  - gestational trophoblastic neoplasia (GTN)
    - definition 441
    - staging 443
    - treatment 444
    - see also specific tumors*
  - glandular breast tissue 341, 341
  - glucose metabolism
    - diabetes diagnosis 253
    - polycystic ovary syndrome and 391
    - pregnancy-related changes 75, **78–79**
    - antepartum care and 86
  - gonadotropin releasing hormone (GnRH)
    - agonists/analogues
      - pelvic pain management 319–320, **320**
      - PMS/PMDD management 418
      - uterine leiomyoma management 462–463
    - amenorrhea and
      - breast-feeding 343
      - secondary amenorrhea 379–380
    - polycystic ovary syndrome and 388
    - pulsatile release 319
  - gonorrhoea 305, 305
    - prophylactic treatment following sexual assault 497
  - granuloma inguinale 309
  - granulosa cells 32, 33, 36
  - granulosa–stromal cell tumors 482
  - group B streptococcus (GBS) 225–226
    - antepartum vaccination/prophylaxis 86–87, 226, 226
    - preterm labor/birth management 142–143
    - PROM and 198
  - diagnosis 225
  - guidelines for prevention of neonatal GBS 143
  - management 225–226, **226**
  - maternal infection 225
  - neonatal infection 225, **226**
  - screening 143, 226, 226
- growth hormone therapy, Turner syndrome 383
- gumma, late/tertiary syphilis 227–228, 306–307
- gynecological surgery 363–385
  - approaches/methods
    - abdominal (laparotomy) approach 364
    - hysteroscopic approach 365–366
    - laparoscopic approach 364–365
    - vaginal approach 363–364
  - common procedures 366–375
  - D & C *see* dilation (dilatation) and curettage (D&C)
  - hysterectomy *see* hysterectomy
  - myomectomy 370–372, **371**, 372
  - oophorectomy 353, 372–373
  - ovarian cystectomy 373, 373–374
  - historical perspective 363
  - office procedures 374–375
  - robotic 371–372, 374
  - uterine atony management 216
  - see also specific techniques/procedures*
- gynecologic history 16, **17**
- H**
- Haemophilus ducreyi* 308
  - haloperidol, pregnancy and 246
  - haploid, definition 42
  - head growth, fetal growth restriction and 181
  - health care provision

- patient-provider communication *see* communication
- perinatal mortality and 233, 234
- social factors/economics 501–506  
*see also* medical economics
- Health Insurance Portability and Accountability Act (1996) 524, 531–532
- health issues
- ethnicity/race and 3, 3
  - sex differences and 3, 8
- health records
- medical economics and 502
  - preventing harm and 531
- heartburn, pregnancy and 256
- heart disease, menopause and 11, 429
- heart rate, fetal *see* fetal heart rate (FHR)
- heat treatment, dysmenorrhea and 400
- HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome 150, **150**, 152
- hematogenous, definition 219
- hemolytic disease 159, 159, 161
- non-D antibodies associated 160, **160**
  - see also* rhesus isoimmunization
- hemorrhage
- cervical, punctate 300, **300**
  - hysterectomy complications 370
  - postpartum *see* postpartum hemorrhage
  - therapeutic abortion and 289
  - see also* bleeding; *specific causes*
- heparinization, pre-eclampsia/eclampsia and 155
- hepatitis B virus (HBV) 309
- preconception evaluation 84
- herpes simplex virus (HSV) 307
- clinical manifestations 222, **222**, 306, 307, 307
  - diagnosis 222
  - pregnancy and 222–223
    - perinatal transmission 222
    - treatment/prevention 223, **223**, 223, 307  - structure 222, 222
  - transmission reduction in discordant couples **309**
  - treatment 223, **223**, 223, 307, **308**
  - type 1 222, 307
  - type 2 222, 307
- heterotopic pregnancy 124
- hidradenitis suppurativa, vulval lesions 449
- highly active antiretroviral therapy (HAART) 223, 224
- hirsutism 394
- management 394, 394
  - polycystic ovary syndrome and 390
  - scoring system 390, 390, 394
  - Sertoli-Leydig cell tumors 483
- history taking 16–17, **17**
- body language and 508, 509
  - chief complaint 16
  - chronic pelvic pain 326–327
  - dysmenorrhea 398–399
  - ectopic pregnancy and 120–122
- endometriosis 316
- fetal growth restriction 184
- gynecologic 16, **17**
- medical complications of pregnancy 257–259
- menopause and 425–426
- obstetric 17, **17**
- open-ended questions 488, 508–509
- patient-centered vs. clinician-centered approach 508
- polycystic ovary syndrome and 389–390, 391, **392**
- post-term pregnancy 267
- preconception care and 81–83
- pre-eclampsia-eclampsia syndrome 152
- present illness 16
- preterm labor/birth and 140, 184, 185
- PROM and 195
- rhesus isoimmunization and 161–162, **162**
- sensitivity/confidentiality 508
- sexual *see* sexual history
- sexual assault 497
- spontaneous abortion 129–130
- therapeutic abortion and 286
- third trimester bleeding 195
- vaginitis diagnosis 295
- HIV infection/AIDS 309
- antiviral drugs 223, 224
  - breast-feeding contraindication 224, 342
  - epidemiology 223
  - infection/life cycle 223
  - pregnancy and 223–225
    - antenatal testing 224, 520–521
    - antepartum measures 224, **225**, 225
    - delivery route 224
    - management goals 223
    - maternal autonomy vs. fetal beneficence 520
    - postpartum measures 224
    - preconception care and 84
    - vertical transmission 224  - prophylactic treatment/testing following sexual assault 497
  - transmission 224
  - virus structure 84, 223, 224
- homicide, maternal mortality 496
- hormonal contraceptive methods 277–279
- breast-feeding and 343–344
  - contraindications/ discontinuation **276**, 279
  - emergency contraception 281–282
  - formulations 277–278, **278**
  - IUDs and 277, 278, 463
  - mechanism of action 277
  - noncontraceptive benefits 279
  - endometriosis-related pelvic pain and 318–319, **319**
  - oligomenorrhea treatment in PCOS 392
- PMS/PMDD treatment 418, **419**
- uterine leiomyoma management 463
- side effects/risks 278–279
- breast cancer and 352
  - see also specific types*
- hormonal factors
- breast cancer 351–352
  - endometriosis and 315, 316
- hormone replacement therapy (HRT) 428–429
- bone density and 428
  - breast cancer and 10–11, 352, 429
  - HRT in survivors 357
  - breast density effects 11, 11
  - cardiovascular disease and 429
  - conjugated equine estrogen (Premarin) **430**
  - endometriosis and 321
  - estrogen vs. estrogen-progestin treatments **431**
  - future 429
  - hot flashes and 427–428
  - WHI study 429, **430**
- hormone therapy
- adenomyosis treatment 322
  - breast cancer prevention 352–353, **358**
  - breast cancer treatment 356
  - contraception and *see* hormonal contraceptive methods
  - endometriosis-related pelvic pain 318–321, **319**, **320**
  - menopausal symptoms *see* hormone replacement therapy (HRT)
  - sexual dysfunction management 491–492, **493**
  - uterine leiomyoma management 7–8
- hospitalization
- pelvic inflammatory disease 312, **313**
  - pre-eclampsia management 153, **154**
  - preterm labor/birth 142, 174
  - third trimester bleeding 215
- 'hot flashes' 423, **425**
- treatment **424**, 427–428
- HPV *see* human papilloma virus (HPV)
- human chorionic gonadotropin (HCG) 65
- ectopic pregnancy and 119, 121, 123
  - heterotopic pregnancy 124
  - molar pregnancy and 442
  - prenatal testing 66
  - spontaneous abortion 129
- human immunodeficiency virus *see* HIV infection/AIDS
- human insulins, pregnancy and 261
- human papilloma virus (HPV) 309
- cervical neoplasia/cancer 309, 435–436, 453
  - etiopathogenesis and 454–455
  - condylomas 309, 448, 454, 456
  - DNA testing 61–62, 455–456
  - cytology and 456, **456**
  - sensitivity/specificity 62
  - see also* Pap smear
  - E6 protein 435–436, 455

- E7 protein 436, 455
- epidemiology of infection 435, 454
- immunosuppression and 454
- oncogenic potential of different types 435, 454
- preventative vaccination 4–5, 455, **459–460**
- vaginal neoplasia/cancer 451
- vulvar neoplasia/cancer 449–450, **452**
- human rights, research subjects and 515
- hydatidiform mole 441–444
- complete 441, **441**, **442**, 442, **444–445**
- diagnosis/monitoring
- HCG levels and 442, 443, **444–445**
- history/examination and laboratory studies 442–443
- ultrasonography 441–442, 442
- epidemiology/prevalence 441, 442
- etiology/pathophysiology 441
- risk factors 442
- oncogenic potential 441
- partial 441, **442**
- pathology 441, 442, **442**
- staging 443
- systemic effects 443
- treatment 443–444, **444–445**
- D & C 442, 443
- false-positive serum HCG and 443–444
- hydramnios (polyhydramnios), definition 167
- hydrops fetalis 161
- hyperbilirubinemia
- definition 107
- management 113
- rhesus isoimmunization 161
- risks 113, 114
- hyperemesis gravidarum 256
- chief complaints/examination 258
- laboratory evaluation 260
- management 262
- hyperprolactinemia
- nipple discharge and 344
- spontaneous abortion and 129
- hypertension
- endometrial cancer and 472
- epidemiology/prevalence 204–205
- pregnancy and *see* hypertension, in pregnancy
- hypertension, in pregnancy 203–210
- chronic (pre-existing) 203
- complications **204**
- diagnosis 204
- epidemiology/prevalence 205
- etiology/pathophysiology 205–206, **206**
- heart enlargement 203
- management *see below*
- pre-eclampsia and 150, 203, 204, 205
- pre-eclampsia vs. 150, 150–151
- subclassification 204
- classification of 203
- definitions 203–204
- diagnosis 204, 206
- etiology/pathophysiology 205, **205**
- gestational *see* gestational hypertension
- high vs. low risk groups 206, **206**
- laboratory evaluations 206, **206**
- medical history 206
- multifetal pregnancies and 170, 174
- physical signs 206
- pre-eclampsia (pregnancy-induced) *see* pre-eclampsia–eclampsia syndrome
- prognosis 208
- special concerns 208
- transient 205, 208
- treatment 207–208
- consultations 207
- diet 207
- pharmacologic therapy *see* anti-hypertensive pharmacologic therapy
- physical activity 207
- hyperthermia, definition 107
- hyperthyroidism
- postpartum 6, 257
- in pregnancy 6
- chief complaints/examination 258–259
- diagnosis 254
- etiology/pathogenesis and 257
- laboratory evaluation 260
- management 262
- hypoactive sexual desire disorder (HSDD) 489–490
- hypocontractile uterus, dystocia 146
- hypophysis, definition 31
- hypothalamic dysfunction, secondary amenorrhea 379–380
- hypothalamic–pituitary–adrenal (HPA) axis
- preterm labor/birth and 139–140, **148**
- puberty role 4, 31
- hypothalamus
- menstrual cycle control **378**
- thermoregulatory transition and 109, 110
- hypothermia, definition 107
- hypothyroidism
- postpartum 6, 257
- preconception care and 84
- in pregnancy 6
- chief complaints/examination 258
- diagnosis 254
- etiology/pathogenesis and 257
- laboratory evaluation 260
- management 262
- hypoxemia, definition 91
- hypoxia
- definition 91
- fetal
- assessment of 91
- late decelerations (FHR) and 94, 95
- hysterectomy 366–370
- adenomyosis treatment 322
- alternatives 366
- approaches 366–370, **367**
- abdominal (laparotomy) 366–367, 368
- laparoscopic 369–370
- relative merits 368
- vaginal 367–368, 369
- see also specific techniques*
- cervical cancer therapy 457
- chronic pelvic pain management 328, **328–329**
- complications 370
- historical aspects 363
- indications 366
- rates 366
- supracervical vs. total 367, **375**
- uterine leiomyoma management 7, **468**
- hysterosalpingogram, infertility diagnosis/evaluation 405
- hysterosalpingography 21–22, 22
- hysteroscopy 23, 23, 365–366
- office setting 375
- pain 375
- principles 365, 365
- tubal ligation 281, 281, 365
- uterine leiomyomas 462
- vaginoscopic approach 375
- I**
- identical monozygotic siblings, definition 167
- imaging 21–23
- adenomyosis 322
- diagnostic value, best evidence **24**
- endometriosis diagnosis 7
- prenatal screening tests 51
- see also specific techniques*
- immune system
- cancer cells and 438
- endometriosis and 315
- isoimmunization, rhesus antigens *see* rhesus isoimmunization
- preterm labor/birth 139
- see also specific components/processes*
- immunoglobulin G (IgG), rhesus isoimmunization and 162–163
- immunoglobulin M (IgM), rhesus isoimmunization and 162–163
- imprinting disorders 50
- isochromosomes and 48
- incompetent cervix *see* cervical insufficiency
- incomplete abortion
- definition 127
- therapeutic abortion 288–289
- incontinence (urinary) *see* urinary incontinence
- incubators 112, 112
- indomethacin, as tocolytic agent 188
- inevitable abortion, definition 127
- infanticide, maternal psychiatric illness and 242
- infant mortality
- gestational age relationship 136

- low birth weight and 179  
maternal psychiatric illness and 242  
preterm birth and 136, 136
- infections/infectious disease  
bacterial *see* bacterial infections  
cervical cancer and *see* human papilloma virus (HPV)  
definitions 219  
hormonal contraception and 279  
hysterectomy complications 370  
IUDs and 280  
pelvic inflammatory disease *see* pelvic inflammatory disease (PID)  
pregnancy and 219–232  
bacterial infections 225–229  
fetal growth restriction and 182  
maternal mortality and 238  
postpartum endometritis *see* puerperal endometritis  
preconception care and 84  
preterm labor/birth and 137–138, 138, 193, 236  
protozoan infections 229–231  
spontaneous abortion and 129  
viral infections 219–225  
protozoan *see* protozoan infections  
therapeutic abortion and 288  
urinary tract 336  
viral *see* viral infections  
*see also specific organisms/infections*
- infertility 403–415  
definition 403  
diagnosis/evaluation 404–405  
anovulation and 407  
hysterosalpingogram 405  
laparoscopy 405, 407  
oocyte pool assessment 404  
outdated tests 405  
ovulation tests 404  
semen analysis 404–405, 405  
standard evaluation 392  
unexplained infertility 407  
epidemiology 403  
ethical issues 411  
etiology/pathophysiology 403, 403–404, 409  
anovulatory cycles 392–393, 407  
breast cancer therapy 356–357  
cervical factors 408  
endometriosis 7, 318, 319, 408  
IUDs and 280, 282  
life-style factors 409  
male factors 406  
pelvic inflammatory disease and 311  
polycystic ovary syndrome and 392, 407  
stress and 411  
therapeutic abortion association 289  
tubal factors 406  
uterine factors 408  
psychosocial aspects 411  
social issues 411  
treatment 406–408
- adoption and 411  
anovulatory infertility 407  
ART *see* assisted reproductive technology (ART)  
cervical factors 408  
endometriosis 408  
male factors 406  
ovarian hyperstimulation syndrome and 410–411  
ovulatory timing and 412  
polycystic ovary syndrome and 392–393, 393, 395, 407  
stepwise approach 407, 408  
tubal factors 406  
unexplained infertility 407  
uterine factors 408  
*see also specific causes*
- inflammation  
intrauterine, preterm labor/birth and 137–138  
mastitis 343, 346, 347  
informed consent 510–511, 510–511, 529  
inhibins 65  
follicular phase and 34  
instrumental vaginal delivery 98, 105, 106  
insulin resistance  
endometrial cancer and 471  
polycystic ovary syndrome and 389, 389, 390, 391  
infertility and 392–393  
insulin treatment, pregnancy and 261  
integrated prenatal screening (IPS) 51, 67, 67–68  
best evidence 54  
contingent sequential testing 68  
stepwise sequential testing 68  
internal genitalia  
definition 25  
embryogenesis 25, 26  
*see also specific structures*  
internal rotation (fetal) 101, 103  
International Federation of Gynecology and Obstetrics (FIGO)  
cervical cancer staging system 454, 457, 458, 459  
endometrial cancer staging system 473, 473  
ovarian cancer staging system 479–480, 480  
International System for Human Cytogenetic Nomenclature (ISCN) 42–43  
interoperable national health record, medical economics and 502  
interstitial cystitis 326  
interstitial (cornual) pregnancy 124, 125  
intertwin membrane 172–173  
thickness 168  
intracytoplasmic sperm injection (ISI) 406  
intrapartum care  
fetal surveillance *see* fetal surveillance
- interventions for altered heart rate 97–98  
*see also specific interventions/procedures*  
intrauterine adhesions, secondary amenorrhea 382  
intrauterine device (IUD) 279–280  
approved types 279  
contraindications 280  
hormonal 277, 278  
uterine leiomyomas and 463  
mechanism of action 279  
risks/side effects 280  
infertility and 280, 282  
pelvic inflammatory disease 311  
intrauterine insemination (IUI) 406  
intrauterine scar tissue, secondary amenorrhea 382  
invasive mole 443  
inversions 47  
in vitro fertilization (IVF)  
indications 409–410  
infertility treatment in PCOS 393  
key steps 409, 409  
iron deficiency anemia, postpartum outcomes 237  
iron supplements 237  
irritable bowel syndrome (IBS), pelvic pain and 326  
isochromosomes 48  
isoimmunization, rhesus antigens *see* rhesus isoimmunization
- J**  
jaundice  
neonatal care 113, 114  
rhesus isoimmunization and 161  
justice 518, 518
- K**  
karyotype, definition 42  
karyotyping 128, 128  
prenatal testing 52, 52, 68, 68  
Kegel exercises 334–335  
kidney(s), maternal changes during pregnancy 76  
*Klebsiella granulomatis* 308  
Klinefelter syndrome (47,XXY) 45–46, 46
- L**  
labetalol, severe postpartum hypertension 208  
laboratory evaluation(s) 19–21  
biopsies 20–21  
chronic pelvic pain 327  
definitions 15–16  
dysmenorrhea 399  
ectopic pregnancy 119, 121  
endometriosis 317  
glucose screening 86  
hypertension in pregnancy 206, 206  
pre-eclampsia 152, 153



- medical complications of  
   pregnancy 259–260  
 menopause and 426  
 multifetal pregnancy 173  
 neonatal care 113  
 Papanicolaou test *see* Pap smear  
 polycystic ovary syndrome and 391  
 prenatal testing 52–53  
 preterm labor/birth and 141–142,  
   179, **180**, 186, **189**  
   PROM and 191, 196–197  
 rhesus isoimmunization  
   diagnosis 162–164  
 serological *see* serological evaluation  
 sexual assault 497  
 therapeutic abortion and 286  
 third trimester bleeding and 197  
 vaginitis diagnosis **295**, 295–296  
   bacterial vaginosis 299, 299  
   vulvovaginal candidiasis 296,  
   296–297  
*see also specific tests*  
 labor augmentation, definition 146  
 labor/delivery 99–106  
   definition 145–146  
   episiotomy and 28, 28, 105, **105**, **106**  
   fetus and  
     cardinal movements 101, **103**, 104  
     fetal characteristics and effects  
       on 101, **102**  
     surveillance *see* fetal surveillance  
     *see also* neonatal period  
   induction  
     ACOG guidelines 234  
     multifetal pregnancy 176  
     post-term pregnancies 268,  
     268–269  
     pre-eclampsia/eclampsia manage-  
     ment 153, 155  
     PROM management 198  
     therapeutic abortion 288  
   mechanics 99–101  
     contraction parameters 99–100  
     pelvis and **100**, 100–101  
   multiple births *see* multifetal  
   pregnancy  
   operative/instrumental vaginal  
   delivery 98, 105, **106**  
   partograph (partogram) 237, 237  
   pathological 135–148  
     definitions 135, **145**, 145–146  
     difficult/prolonged *see* dystocia  
     obstructed 237–238  
     preterm *see* preterm labor/birth  
     *see also* post-term pregnancy  
   phases 99, 104, **104**, 147  
   physiologic aspects 99, 99  
   prevention *see* tocolytic therapy  
   progress **104**, 104, 104–105  
   stages 104  
     dystocia management 147–148  
     normal vs. abnormal progress 146  
   ‘three P’s’ 135  
   urinary incontinence and 333  
 lactation 341, 342  
   disorders associated 343  
     *see also* breast-feeding  
   lactobacilli, normal vaginal flora 294  
   lactogenic hormones 342  
   lambda sign 172  
   laminaria tents 287, 288  
   laparoscopically assisted myotomy  
   (LAM) 466  
   laparoscopic morcellator 465–466  
   laparoscopic myolysis 467  
   laparoscopic uterine artery occlusion  
   (LUAO), uterine leiomyomas 466  
   laparoscopy 23, 364–365  
     ectopic pregnancy management 122,  
     125  
     endometriosis  
       diagnosis 7  
       treatment 321, **322**, **323**  
     hysterectomy 369–370  
     infertility diagnosis/evaluation 405,  
     407  
     laparotomy vs. **364**, 364–365,  
     369–370  
     method 364, 365  
     ovarian cystectomy 373  
     post-operative effects/recovery 365,  
     370  
     tubal ligation 281, 281  
     uterine nerve ablation, dysmenorrhea  
     and 401  
   laparotomy 364  
     ectopic pregnancy management 122  
     hysterectomy and 366–367  
     laparoscopy vs. **364**, 364–365,  
     369–370  
   latency, definition 219  
   latent phase (labor) 104, **104**, **104**  
   late pregnancy bleeding *see* third tri-  
   mester bleeding  
   lean engineering, medical economics  
   and 502  
   legal issues 527–533  
     adverse outcomes and *see* adverse  
     outcomes  
     breaches of duty 530  
     causation 530  
     certification 528  
     common areas of increased liability  
     risk 530–531  
     communication importance 528, 530  
     credentialing 528  
     damage done 530  
     disclosing medical errors 513, 529  
     documentation 531  
     Health Insurance Portability and  
     Accountability Act 524, 531–532  
     informed consent 510–511,  
     **510–511**, 529  
     lawsuit effects on OB/GYN  
     practice 527, **527**  
     licensure 528  
     maternal autonomy vs. fetal  
     beneficence 520  
     negligence 530  
     privileges 528  
   risk management 530  
   standards of care 528  
   therapeutic abortion 285  
   *see also* ethical issues  
 leiomyomas, uterine *see* uterine lei-  
 omyomas  
 leiomyosarcomas, uterine 474–475  
 levonorgestrel-releasing intrauterine  
 system 401  
 licensure 528  
 lichen planus, vulvitis 302–303  
 lichen sclerosus, vulvitis 302  
 lichen simplex chronicus, vulvitis 302  
 life-style  
   fertility/infertility and 409  
   fetal growth restriction and 182–183  
   pregnancy and preconception  
     care 82, **82**, **82**, **83**  
   premenstrual syndrome 417–418  
   urge incontinence management  
   335–336  
   *see also specific factors*  
 Liley curve 163, 163  
 lipoma, breast 347  
 listeria 238  
 lithotomy 18, 18  
 LNG-20 (Mirena) IUD 279  
 lobular carcinoma in situ 347  
 lobular-type epithelial proliferation 347  
 ‘locked twins’ 177, 177  
 longevity  
   medical economics and 501  
   poor vs. wealthy countries 505  
   *see also* mortality  
 low birth weight 179–190  
   consequences 179, 179  
   definition 135  
   therapeutic abortion association 289  
   *see also* fetal growth restriction  
   (FGR); preterm/premature babies  
 lubricants, vaginal dryness and 491  
 lung function  
   asthma diagnosis 252, 252  
   maternal changes during  
   pregnancy 76, 76  
 lung maturation 107  
   antenatal steroids and *see* steroid-  
   induced lung maturation  
 luteal cells 36  
 luteal phase (menstrual cycle) 36,  
 36–37  
 luteinizing hormone (LH)  
   follicular phase and 34, 34, 35  
   luteal phase and 36  
   ovulation and 35  
   home testing, best evidence **38**  
   polycystic ovary syndrome and 391  
 luteolysis 37  
 lymphadenectomy  
   cervical cancer therapy 457  
   endometrial cancer and 474  
 lymphadenopathy  
   definition 219  
   syphilis 227  
 lymph nodes

- breast cancer involvement **355, 355**, 355–356
- breast examination 341
- lymphogranuloma venereum (LGV) **308, 308**
- Lynch syndrome 436
- endometrial cancer and 436, 473
- M**
- macroprolactinomas, treatment 381
- magnesium sulfate
- pre-eclampsia and 236
- as tocolytic **186, 187**
- magnetic resonance imaging (MRI)
- adenomyosis diagnosis 322
- breast cancer screening 354, 354
- uterine leiomyomas
- diagnosis 371, 462
- MRI-guided focused ultrasound therapy 467
- malaise, definition 219
- male(s)
- age-related changes in sexual activity 492
- breast cancer 351
- condoms 277
- females vs. *see* sex differences
- infertility treatment 406
- sexual dysfunction **488, 488**
- sexual responses 487–488
- sterilization (vasectomy) 281
- mammography
- age effects 345
- breast cancer screening 353–354, 354
- breast mass evaluation/
- diagnosis 345, 354
- fat necrosis and 347, 348
- HRT effects 11, 11
- marsupialization of Bartholin cyst 447, 447
- mastalgia 344
- mastectomy, risk reducing bilateral 353
- mastitis 343, 347
- chronic cystic 346
- maternal age
- adolescent pregnancy 5, 81
- chronic hypertension and 205
- ectopic pregnancy 119
- mortality rates and 234–235
- older mothers 82, 128
- Edwards syndrome (trisomy 18) 45
- multifetal pregnancies 169, 174
- trisomy 13 (Patau syndrome) 44
- trisomy 21 (Down syndrome) and 44, 44, 65, 68
- preconception care and 81–82
- spontaneous abortion and 128
- therapeutic abortion risk 286
- maternal blood count, PROM diagnosis 197
- maternal–fetal physiology 75–80
- fetal physiology 77–78
- amniotic fluid 78
- endocrinology 78, 78
- fetal circulation 77–78
- maternal physiology 75–77
- carbohydrate metabolism 75, **78–79, 86**
- cardiovascular system 75, 75–76
- labor 99, 99
- placental *see* placenta
- renal function 76
- respiratory system 76, 76
- maternal mortality 233–240
- definition 233
- epidemiology 234–235, 235
- etiologies 234, 234–235
- ectopic pregnancy 122, 125
- infectious 238
- iron deficiency 237
- obstructed labor and 237–238
- postpartum hemorrhage 213, 236
- pre-eclampsia/eclampsia 149, 236
- third trimester bleeding 191, 236–237
- homicide and 496
- maternity service provision and 505
- prevention 236–238
- antepartum care and 236
- infection control 238
- iron supplementation 237
- magnesium sulfate 236
- partograph and 237, 237
- symphysiotomy and 237–238
- uterogenic agents 236–237, **239**
- therapeutic abortion risk 286
- see also specific causes*
- maternity services, reduction of mortality and 505
- mechanical stimulators, sexual dysfunction 491
- meconium
- fetal metabolic status and 97
- post-term fetus and inhalation 266, 269
- meconium aspiration syndrome 269
- medical abortion 286–287, **287, 290**
- medical documentation 531
- medical economics 501–506
- developed countries and 501–505
- chronic illness management 503
- ending-of-per-case payments 503–504
- evidence-based medicine 502
- generic medicines and 502
- health care costs as percentage of GDP 501, 502
- improving quality 504, **504–505**
- interoperable national health record 502
- intervention in last weeks of life 503
- preventative medicine 503, **503**
- professional liability reform 504
- rationing health care 504
- regional variations and best practice **506**
- waste reduction (lean engineering) 502
- developing/poor countries 505
- health disparities 505
- population health effects on
- economic growth/stability 501
- rapidly growing economies 505
- medical education
- ethical issues and 517, 522
- legal issues and 532, 532
- medical errors, disclosing 513, 529
- medical ethics *see* ethical issues
- medical research, human rights 515
- meiosis 42, 43
- melanocytic nevi, vulval lesions 448
- melanoma, vulval lesions 448
- membrane sweeping/stripping 268, 268
- men *see* male(s)
- menarche 4, 31, 382
- age at
- breast cancer and 351
- factors affecting 423
- definition 15–16, 31
- Mendelian genetics 41, 49
- disorders 49
- see also specific types*
- menometrorrhagia, definition 384
- menopausal transition 421–422
- menopause 10–12, 421–431
- age of onset 10, 421, 423
- breast cancer and 351
- factors affecting 423
- breast cancer and HRT 10–11
- breast cancer survivors 357
- clinical presentation/features 10, 425–426
- cognition and 426
- endometriosis and 321
- heart disease 11, 429
- hot flushes 423, **424, 425, 427**
- laboratory evaluations 426
- mood disorders 426
- osteoporosis 12, 12, 428
- physical examination 426
- racial differences 425
- sexual dysfunction 425–426
- urinary incontinence 12, 12, 426
- vaginal symptoms 301, 425, 428
- see also specific symptoms*
- definition 422
- etiology/epidemiology 423
- physiology 423
- premature *see* premature ovarian failure
- surgical 427
- treatments 427–429
- bone density and 428
- breast cancer and 429
- cardiovascular system and 429
- hot flushes **424, 427–428**
- vaginal symptoms **424, 428**
- see also* hormone replacement therapy (HRT)

- see also perimenopause;  
 postmenopause  
 menorrhagia, definition 384  
 menorrhea, definition 31  
 menses  
   definition 31  
   initiation see menarche  
   see also menstruation  
 menstrual cycle 31–40, 378  
   absence see amenorrhea  
   bleeding see menstruation  
   breast-feeding and 343  
   definitions 31  
   hormonal contraception and 279  
   hypothalamic control **378**  
   initiation (menarche) see menarche  
   irregularity and the menopause 425  
   see also menopause  
   normal lengths 384  
   phases 32, 32–37  
     follicular see follicular phase (menstrual cycle)  
     luteal phase 36, 36–37  
     ovulation 35–36, 36, **38**  
     see also fertilization  
   polycystic ovary syndrome and 389  
   premenstrual syndrome see  
     premenstrual syndrome (PMS)  
   vaginal discharge and 294  
   see also specific phases  
 menstruation  
   abnormal bleeding 384–385  
   absence see amenorrhea  
   definition 16  
   painful see dysmenorrhea  
 mental health issues 8–9  
   following sexual assault 497  
   see also psychiatric disorders; specific disorders  
 mesosalpingeal cysts 483  
 metabolic acidosis, definition 91  
 metabolic disorders  
   polycystic ovary syndrome and  
     388–389, **389**, 389, 390, 391  
   see also specific disorders  
 metabolic rate, neonatal period 110  
 metabolic status, fetal monitoring 97  
 metabolic syndrome, polycystic ovary  
 syndrome and 388, **389**  
 metformin, anovulatory infertility treat-  
 ment in PCOS 392–393, **395**  
 methotrexate, ectopic pregnancy man-  
 agement 122–123  
   adverse effects 123, **124**  
   efficacy 123  
   indications/contraindications 123, 123  
   protocols 123  
 metronidazole, trichomoniasis  
 treatment 301  
 metrorrhagia, definition 384  
 microprolactinomas, treatment  
 380–381  
 microsatellite instability 49–50  
 midpelvis 101  
 mifepristone, medical abortion  
 286–287, **287**  
 ‘milking,’ ectopic pregnancy manage-  
 ment 122  
 Mirena (LNG-20) IUD 279  
 miscarriage see spontaneous abortion  
 mismatch repair (MMR) genes, cancer  
 and 436, 472, 479  
 misoprostol  
   postpartum hemorrhage  
     management 236–237, **239**  
   spontaneous abortion  
     management 130  
   therapeutic abortion and 288  
 missed abortion, definition 127  
 mitochondrial disorders 49  
 mitosis 42, 43  
 moisturizers, vaginal dryness and 491  
 molar pregnancy 441–446  
   benign see hydatidiform mole  
   definition 127, 441  
   dilation (dilatation) and  
   curettage 442, 443  
   HCG levels and 442, 443  
   false-positives 443–444  
   malignant see gestational  
   trophoblastic neoplasia (GTN)  
   staging 443  
   systemic manifestations 443  
   see also specific tumors  
 molluscum contagiosum, vulval  
 lesions 448  
 monosomies 44, 46–47  
   isochromosomes and 48  
   see also specific disorders  
 monosomy X (45,X; Turner syndrome)  
   see Turner syndrome  
 monozygotic siblings  
   definition 167  
   twin birth rate 168  
 Montevideo unit 100  
 mood disorders, menopause and 426  
 mood stabilizers, breast-feeding and 248  
 moral rules 519  
 moral theories **518**  
 morning-after pill 281–282  
   following sexual assault 497  
 morning sickness 256  
 mortality 233–240  
   definitions 233  
   developing countries 505  
   maternal see maternal mortality  
   perinatal see perinatal mortality  
   poor vs. wealthy countries 505  
   third trimester bleeding and 191  
 mosaicism  
   definition 42  
   placental 68  
 Müllerian duct  
   anomalies  
     common types 25, **25**, 27  
     definition 16  
   embryogenesis 25, 26  
 multichannel urodynamics 333–334  
 multifactorial inheritance 49  
 multifetal pregnancy 167–178  
   definitions 167  
   diagnosis/assessment 168, 168,  
     171–173  
   amniocentesis 168, 172, 172  
   caveats 172–173  
   chorionicity see chorionicity  
   history/chief symptoms 171  
   laboratory evaluations 173  
   physical examination 171  
   ultrasonography 168, 168,  
     171–173, 172, **173**  
   epidemiology 168, **169**  
   etiology 169–170  
   ART and 168, 169–170, 410  
   genetics 169  
   maternal age and 169, 174  
   fetal physiology/pathophysiology  
   170, 170–171, 174  
   fetal growth restriction and 182  
   higher-order pregnancies 168  
   biophysical profiles 174  
   labor/delivery 178  
   labor/delivery 175–178  
   anesthesia 176  
   duration 176  
   fetal monitoring 176  
   induction/stimulation 176  
   ‘locked twins’ 177, 177  
   mode of delivery 176–177  
   preterm labor/birth and 136, 139,  
     174–175  
   see also preterm labor/birth  
   preventing potential complica-  
   tions 175–176  
   timing interval between deliver-  
   ies 177  
   timing of 177  
   vertex–nonvertex delivery 177  
   vertex–vertex delivery 176–177  
   management 173–175  
   antepartum 173–174  
   fetal reduction 175, **178**  
   preterm labor prevention see under  
   preterm labor/birth  
   maternal physiology/  
   pathophysiology 170, 174  
   see also twins  
 multiple birth  
   definition 167  
   see also multifetal pregnancy  
 multistep carcinogenesis 437  
 musculoskeletal system, pelvic pain  
 and **325**, 326  
 myalgia, definition 219  
 myofascial pain syndromes, pelvic  
 pain 326  
 myomas  
   definition 16  
   see also uterine leiomyomas  
 myomectomy 370–372, 464–466  
   embolization/occlusion vs. **468**  
   indications 371, **371**  
   laparoscopic suturing as limiting  
   factor 464, 466

- procedure 371–372, 372, 464–465, 465–466  
 as treatment of choice 463  
 myometrium 28  
 adenomyosis and 321
- N**
- National Commission for the protection of Human Subjects of Biomedical and Behavioral Research 515  
 National Institutes of Health (NIH), polycystic ovary syndrome criteria 387, **387**  
 National Research Act (1974) 515  
 National Surgical Adjuvant Breast and Bowel Project (NSABP) 352–353  
 natural family planning 276  
 nausea, pregnancy-related (morning sickness) 256  
 negligence 530  
*Neisseria gonorrhoeae* 305, 305  
 neonatal care 110–113  
   breast-feeding/nutrition 112, **114**  
   *see also* breast-feeding  
   definitions 107  
   discharge procedures 113  
   ethical dilemmas 522  
   evaluation and resuscitation 110–111  
   general care 111  
   home routines 113  
   identification and security 111  
   initial physical assessment/prophylaxis 112  
   jaundice management 113, **114**  
   laboratory evaluations 113  
   respiratory care 107–108, **111**  
   Apgar score 107, 108, 110, **110**  
   evaluation and resuscitation 110–111  
   stooling 113  
   thermal regulation 111–112  
   incubators 112, **112**  
   voiding micturition 113  
 neonatal period 107–115  
   breast tissue 344  
   care during *see* neonatal care  
   circulatory transition 108, **109**  
   definition 107  
   drug toxicity/withdrawal and, antidepressants 245, **245**  
   maternal psychiatric illness and 242  
   metabolic rate 110  
   mortality *see* perinatal mortality  
   respiratory transition 107–108  
   sepsis, GBS and 225  
   thermoregulatory transition 108–110  
   heat loss/gain 110  
   hypothalamus and 109, **110**  
   neonatal thermoregulation 108–109  
   thermal neutral zone 109, **109**  
   thermoregulatory behaviors 110  
 neural tube defects (NTDs)  
   multifactorial inheritance 49  
   screening 69  
 neuraxial anesthesia  
   abnormal labor and 146–147  
   multifetal pregnancy/birth 176  
 neuroleptics (antipsychotic drugs)  
   breast-feeding and 248  
   pregnancy and 246  
 neuropathic pain 326  
   management 328  
 newborn care *see* neonatal care  
 newborns (neonates) *see* neonatal period  
 nifedipine, dysmenorrhea treatment 401  
 nipple(s) 341, **341**  
   accessory 344  
   discharge 343, **344**  
 nitrazine test 191  
 nitroimidazole, trichomoniasis treatment 301  
 nociceptive pain 326  
 noncoital nonsexual pain disorder 490  
 nonmaleficence 518, **518**  
 non-Mendelian disorders 49–50  
 non-steroidal anti-inflammatory drugs (NSAIDs)  
   dysmenorrhea treatment 400, **400**  
   pelvic pain and endometriosis management 318–319  
 nonstress test, post-term pregnancy 267  
 nontubal ectopic pregnancy 124–125, **125**  
 nuchal translucency 51, 66, 66  
   definition 65  
 nutrition  
   antepartum care and 87  
   birth to adolescence 5  
   breast-feeding and  
     benefits to newborn 112  
     mother 9–10  
   fetal growth restriction and 182  
   hypertension management 207  
   infertility and 409  
   multifetal pregnancy and 173  
   pregnancy, diabetes and 261  
   reproductive age women and offspring 9–10, **10**
- O**
- obesity  
   birth to adolescence 5  
   endometrial cancer and 471, **472**  
   fertility and 392, 409  
   morbid, definition 393  
   polycystic ovary syndrome and 390  
   infertility and 392  
   management 392, 393  
   pregnancy risks 87  
 obsessive compulsive disorder (OCD) 9, 246  
 obstetric history 17, **17**  
 obstetric practice  
   lawsuit effects on 527, **527**  
   preterm labor/birth and 136, **137**, 182  
   *see also* specific components  
 obstructed labor, maternal mortality/morbidity 237–238  
 office-based procedures/surgery 374–375  
   vaginitis diagnosis **295**, 295–296  
 oligomenorrhea  
   differential diagnosis 389  
   tests/evaluation 404  
   treatment in PCOS 392  
 oligo-ovulation, polycystic ovary syndrome 390, 392  
 oncogenes 437  
 oocyte 32  
   changes in number during lifetime 421, **421**, 422  
   definition 31  
   pool evaluation 404  
 oocyte maturation inhibitor (OMI) 32  
 oögonia  
   definition 31  
   developmental changes 32  
 oophorectomy 372–373  
   bilateral  
     PMS/PMDD management 418  
     risk reducing (cancers) 353, 373  
   indications 373  
 operative vaginal delivery 98, 105, **106**  
 oral contraceptive pills (OCs) 278, **278**  
   breast cancer risk 352  
 oral diabetic drugs, pregnancy and 261  
 orgasm, disorders 490  
 osteoporosis  
   breast cancer survivors and 357  
   diagnosis 12  
   management 12, 12  
   menopause and 12, 428  
 ovarian cancer  
   diagnosis  
     germ cell tumor markers **481**  
     history/physical examination 479  
     postmenopausal women 477–478, **478**  
     premenopausal women 477, **478**  
     serum CA-125 477–478, 479  
     surgical–pathological 479–480  
     ultrasound 477, 479  
   endometrial cancer and 474  
   epidemiology 478, 479  
   epithelial 478–480  
   FIGO staging 479–480, **480**  
   germ cell tumors **481**, 481–482  
   management  
     chemotherapy 480  
     combined surgical/adjuvant approach **483**  
     optimal surgical cytoreduction 480  
     risk-reducing surgery **438**, 481  
   metastatic 481  
   pathology/pathogenesis  
     BRCA1/BRCA2 mutations 437, **438**, 479

- germ-line mutations in MMR genes 436, 479  
 histological subtypes 477, 477, 478–479  
 metastatic potential 480  
 risk factors 479  
 pregnancy and 480–481  
 sex cord–stromal tumors 482–483  
 survival rates by stage **480**  
 tumors of low malignant potential (borderline tumors) 478  
*see also specific types*
- ovarian cysts  
 ‘dermoid’ (teratomas) 481  
 differential diagnosis in  
 premenopausal women 477, **478**  
 endometriosis and 316, 317–318  
 epidemiology 477  
 laparoscopic removal 373, 373–374  
 structures giving rise to 477, 477  
*see also polycystic ovary syndrome (PCOS)*
- ovarian fibromas 482–483  
 ovarian hyperstimulation syndrome (OHSS) 410–411  
 ovarian hyperthecosis, virilization and 394  
 ovarian torsion 478  
 ovary(ies)  
 aging 421–431  
 clinical presentation 425–426  
 definitions 421–422  
 factors affecting 423  
 key stages 421–422, **422**  
 oocyte numbers and 421, 421, 422  
 physiology 423–424  
*see also menopause; perimenopause; postmenopause*
- anatomy 29  
 common developmental abnormalities **25**  
 dysfunction  
 amenorrhea and 381  
 polycystic ovaries *see* polycystic ovary syndrome  
 primary (premature) failure *see* premature ovarian failure (POF)  
*see also infertility; specific conditions*
- ectopic pregnancy 125  
 hyperstimulation syndrome 410–411  
 masses 477–483  
 cysts *see* ovarian cysts  
 epithelial 478–480  
 evaluation 477–478  
 germ-cell tumors **481**, 481–482  
 histological subtypes 477, 477  
 malignant *see* ovarian cancer  
 ovarian torsion 478  
 sex cord–stromal tumors 482–483  
*see also specific types*  
*see also entries beginning ovarian*
- overflow incontinence 333  
 ovulation 35–36  
 home testing, best evidence **38**
- infertility management and timing assessment **412**  
 polycystic ovary syndrome and 390  
 regulation 36  
 testing 404  
 ovum, blighted 127  
 oxytocin  
 dystocia management 147  
 inhibitors, preterm labor prevention 188  
 uterine atony management 216, **216**  
 uterine rupture risk 194
- P**
- p53  
 HPV effects 436, 455  
 type II endometrial cancer and 472
- pain  
 abdominal *see* abdominal pain  
 assessment 327, 327  
 back pain *see* back pain  
 breasts (mastalgia) 344  
 endometrial biopsy 375  
 neuropathic 326, 328  
 nociceptive 326  
 office hysteroscopy 375  
 ovarian torsion 478  
 pelvic *see* pelvic pain  
 sexual dysfunction and 490  
 uterine leiomyomas 462, 463  
*see also specific types/locations*
- palpation  
 abdominal examination 18, 18  
 definition 16
- pancreas, fetal 78  
 Papanicolaou test *see* Pap smear  
 papilloma, breast 346  
 Pap smear 19–20, 57–64  
 abnormal appearance 60  
 Auto-Pap Screening System 20  
 bacterial vaginosis and 299  
 best evidence for effectiveness **62–63**  
 conventional 20, 59, 59  
 liquid-based (ThinPrep) 20, 59, 59–60  
 normal appearance 59  
 sample collection/technique 20, 59, 59  
 screening guidelines 61, **61**  
 sensitivity/specificity **60**, 60–61, **61**  
 terminology **57**, 57–58, **58**  
 detection rates and **61**, **61**  
 trichomoniasis and 301
- Paragard (TCu380A) IUD 279  
 parathyroid hormone (PTH), bone density effects 428  
 paresthesia, definition 219  
 partial hydatidiform mole 46–47  
 partograph (partogram) 237, 237  
 parturition *see* labor/delivery  
 Patau syndrome (trisomy 13) 44–45, 45  
 paternal rhesus antigen zygosity assessment 159  
 patient care 3–72
- communication between patient–provider *see* communication  
 definition of OB/GYN care 3  
 genetic aspects *see* genetics/genomics  
 importance of 3  
 life-long 3–14  
 birth to adolescence 4–5  
 menopause 10–12  
 reproductive years 5–10  
*see also specific aspects*
- patient explanatory model 513–514  
 patient–provider communication *see* communication  
 PCOS *see* polycystic ovary syndrome (PCOS)
- pedigree, definition 42  
 pelvic examination 18, 18  
 ectopic pregnancy 120  
 preterm labor 184
- pelvic inflammatory disease (PID) 311–314  
 clinical features 311  
 definition 311  
 diagnosis 312, **312**  
 etiology/pathophysiology 311  
 long-term consequences 311  
*see also infertility*  
 risk factors 311  
 treatment 312–313  
 in-patient vs. outpatient 312, **313**  
 regimens **312**  
 tubo-ovarian abscess 313  
*see also sexually transmitted diseases (STDs); specific causes*
- pelvic inlet 100–101  
 pelvic organs  
 normal anatomy 332  
 prolapse 331–332, 332  
*see also specific organs*
- pelvic outlet 101  
 pelvic pain  
 assessment 327, 327  
 chronic 325–330  
 definition 325  
 epidemiology/prevalence 326  
 history 326–327  
 laboratory studies 327  
 physical examination 327  
 diagnosis 325  
 etiologies 325, **325**  
 ectopic pregnancy 119  
 endometriosis 315, 316, 318–321  
 IBS 326  
 musculoskeletal 326  
 pelvic inflammatory disease 311  
 urinary tract 326  
*see also specific causes*
- management 327–328  
 aromatase inhibitors 320  
 combined hormonal/surgical 321  
 cyclic hormonal contraceptives plus NSAIDs 318–319  
 danazol 320  
 GnRH analogues 319–320, **320**  
 interdisciplinary pain practice 328

- neuropathic pain 328  
 noncyclic combination contraceptives 319  
 progestin-only contraceptives 319, **319**  
 surgical 321, **323**, 328, **328–329**, 373  
 menopause effects 321  
 pathophysiology 326  
 pelvic relaxation 331–332, 332  
 pelvimeter 100, 100  
 penetrance, genetic disorders 49  
 penicillin  
 GBS management 225–226  
 syphilis management 229, 307  
 per-case payments 503–504  
 perimenopause 421–431  
 definition 422  
 physiology 423  
 prevention of FSH oscillation in 423, **424**  
 symptoms/signs 425–426  
*see also* menopause; postmenopause  
 perinatal mortality 108, 108, 233–240  
 definitions 233  
 early 233  
 epidemiology 233–234, 234  
 etiologies 233–234  
 fetal growth restriction and 180–181  
 preterm/premature babies 136, 136, 233, 234, 235  
*see also specific causes*  
 late 233  
 management/prevention 235–236  
 prenatal care role 236  
 preterm labor and *see under* preterm labor/birth  
 maternal psychiatric illness and 242  
 post-term pregnancy and 268  
 rate 233  
 periods *see* menstruation  
 peristalsis 255, 256  
 peritoneal lining metaplasia, endometriosis and 315  
 persistent genital arousal disorder (PGAD) 490  
 persistent occiputoposterior position (POP), dystocia and 147  
 phenotype, definition 42  
 phyllodes tumor 346  
 physical assessment, dysmenorrhea 399, 399  
 physical examination 17–19  
 abdominal examination 18, 18  
 back pain assessment 252, 252  
 bimanual examination 19, 19  
 breasts 341–342  
 chronic pelvic pain 327  
 ectopic pregnancy 120  
 endometriosis 316, 316  
 external genitalia inspection 18  
 fear/anxiety associated 17  
 fetal growth restriction 185–186  
 medical complications of pregnancy 257–259  
 menopause and 426  
 pelvic examination 18, 18  
 pelvic inflammatory disease (PID) 312  
 postpartum hemorrhage 214–215  
 post-term pregnancy 267  
 pre-eclampsia–eclampsia syndrome 152  
 preterm labor/birth and 141, 184–185  
 PROM and 195–196  
 rectovaginal examination 19, 20  
 rhesus isoimmunization diagnosis 162  
 sexual assault 497  
 sexual dysfunction and **489**  
 speculum examination 18–19, 19  
 spontaneous abortion 130  
 therapeutic abortion and 286  
 third trimester bleeding 196  
 vaginitis diagnosis 295  
*see also specific aspects*  
 physical therapy, sexual dysfunction 491  
 Pinard stethoscope 96, 96  
 Pipelle biopsy 21, 22  
 Piper forceps 106  
 pituitary dysfunction, secondary amenorrhea 380–381  
 placenta 76–77  
 compartments 77, 77  
 development 76, 76  
 inner layer 76–77  
 late decelerations in FHR and 95  
 outer layer 77  
 preterm labor/birth and 139  
 spontaneous abortion and 129  
 tumors *see* molar pregnancy  
*see also specific disorders*  
 placenta accreta  
 definition 211  
 delivery and 215  
 diagnosis 212  
 epidemiology/prevalence 212  
 etiology/pathophysiology 213, 213  
 risk factors 213  
 therapeutic abortion and 289  
 placental abruption  
 classification/grading 193, 211  
 definition 191, 211  
 diagnosis  
 history/chief complaint 195, 195  
 physical examination 196  
 epidemiology/prevalence 192, 212  
 etiology/pathophysiology 193, 213  
 management 199  
 delivery and 215  
 types/locations 215  
 placental insufficiency, pre-eclampsia and 205  
 placenta previa  
 classification/grading 193, 194, 211, 211  
 definition 191, 211–212  
 diagnosis 212, 214  
 history/chief complaint 195  
 physical examination 196, 214  
 ultrasonography 214, **217**  
 epidemiology/prevalence 213  
 etiology/pathophysiology 193, 213  
 management 199, 200  
 transvaginal ultrasound diagnosis 192  
 placenta site trophoblastic tumor (PSTT) 444  
 placentation, definition 167  
 PMS *see* premenstrual syndrome (PMS)  
 polycystic ovary syndrome (PCOS) 387–396  
 definition 387  
 diagnosis **387**, 387–388  
 history/chief complaint 389–390, 391, **392**  
 laboratory evaluation 391  
 physical examination 390  
 TVUS 388, 388, 391  
 epidemiology/prevalence 388  
 etiology/pathophysiology 388–389  
 metabolic abnormalities 388–389, **389**, 389, 390, 391  
 reproductive hormones 388, 388  
 hirsutism and  
 hyperandrogenism 390, 390, 394  
 menstrual dysfunction 389, 392  
 oligo-ovulation 390  
 treatment 391–394, **392**  
 dysfunctional uterine bleeding 394  
 hirsutism 394, 394  
 infertility 392–393, **393**, **395**, 407  
 obesity 392, 393  
 oligomenorrhea 392  
 polygenic traits/disorders 49  
 polyhydramnios (hydramnios), definition 167  
 polymenorrhea, definition 384  
 polymerase chain reaction (PCR)  
 herpes simplex virus diagnosis 222  
 prenatal testing 53  
 syphilis detection 228  
 polyploidy  
 definition 43  
 disorders 43–46  
 sex chromosomes and 46–47  
*see also specific conditions*  
 polyzygotic birth, definition 167  
 POP-Q system 331  
 postabortal endometritis 288  
 postcoital test, infertility diagnosis/evaluation 405  
 posterior pelvic provocation test 252, 253  
 post-maturity syndrome 266  
 postmenopause 421–431  
 adnexal mass evaluation 477–478, 479  
 definition 422  
 early vs. late 422

- 'hot flushes' 423, **424**  
 HRT *see* hormone replacement therapy (HRT)  
 increasing length of 421  
*see also* menopause; perimenopause
- postpartum ('baby') blues 247  
 postpartum depression 9, 242, 247  
 antidepressants and 247–248, **248**  
 screening 247
- postpartum hemorrhage 211–218  
 definitions 211  
 diagnosis 212  
 history/chief complaint 214  
 physical examination 214–215  
 epidemiology/prevalence 212–213  
 etiology/pathophysiology 211, 213–214  
 management 215–217, 236–237, **239**  
 Sheehan syndrome and 381  
*see also* third trimester bleeding;  
*specific causes*
- postpartum mood disorders 247–249  
 nonpharmacological approaches 248  
 screening 247  
*see also specific conditions*
- postpartum period  
 definition 107  
 hemorrhage *see* postpartum hemorrhage  
 infection 211–218  
 puerperal endometritis *see* puerperal endometritis  
*see also specific infections/organisms*
- newborn care *see* neonatal care  
 psychiatric disorders and 242  
*see also specific conditions*
- postpartum psychosis 248  
 postpartum sexual dysfunction 492  
 postpartum thyroid disorders 257  
 postpartum tubal ligation 280, 280–281
- post-term pregnancy 265–270  
 definition 265  
 diagnosis 265, 265  
 history/chief complaint 267  
 physical examination 267  
 etiology/pathophysiology 266  
 fetal consequences/risks 266, 266, 268, 269  
 management/treatment  
 options 268–269  
 41–42 weeks 268  
 complications 269  
 delivery route 268  
 elective vs. expectant **269**  
 induction 268, 268–269  
 maternal consequences 266  
 perinatal mortality and 268  
 prevalence 266
- posttraumatic stress disorder (PTSD) 9  
 following sexual assault 497, **498**
- posture, back pain and 260  
 Prader-Willi syndrome 50  
 preconception care 81–85  
 chronic disease and 84–85  
*see also specific diseases*
- definition 81  
 dietary supplements 85, **89**  
 history and 81–83  
 life-style factors 82, **82**, **82**, **83**  
 maternal age 81–82  
 importance 81  
 serological evaluation 84  
 standard recommendations **85**
- pre-eclampsia–eclampsia syndrome 149–157  
 chronic hypertension and 150, 203, 205  
 diagnostic issues 204  
 complications/risk 149  
 definitions 149–150, 203  
 diagnosis 149–150  
 criteria **149**  
 differential diagnosis 150, 150–151  
 HELLP syndrome 150, **150**, 152  
 history 152  
 laboratory evaluations 152, **153**  
 physical examination 152  
 proteinuria requirement 149, **149**, 152
- eclamptic convulsions 149, 150, 155  
 epidemiology/prevalence 151  
 etiology/pathophysiology 151, 151–152, 205  
 gestational hypertension and 204  
 stages 150  
 treatment **156**, 206–208, 236  
 antepartum steroids 153  
 antihypertensives 155–156, **156**, 207–208  
 conservative 153, **157**  
 eclampsia 155  
 fetal assessment 153, 155  
 fluid balance 154  
 hospitalization 153, **154**  
 labor induction 153, 155  
 maternal assessment 153, 154  
 pre-eclampsia 153–154  
 severe pre-eclampsia 154–155  
 thromboprophylaxis 155
- pregnancy  
 antepartum care *see* antepartum care  
 dietary supplements 85  
 domestic violence and 495, 496  
 ectopic *see* ectopic pregnancy  
 following breast cancer therapy 357  
 hypertension and *see* hypertension, in pregnancy  
 infectious diseases *see* infections/infectious disease  
 lactogenic hormones 342  
 life-style factors and risks 82, **82**, **82**, **83**  
 maternal age *see* maternal age  
 medical complications 251–264  
 chief complaints/examination 257–259  
 definitions 251  
 diagnosis 252–254  
 epidemiology/prevalence 254  
 etiologies/pathogenesis 255–257  
 laboratory evaluations 259–260  
 treatment options 260–262  
*see also specific conditions*
- multifetal *see* multifetal pregnancy  
 obesity risks 87  
 obstetric history 17, **17**  
 ovarian cancer and 480–481  
 physiologic changes *see* maternal-fetal physiology  
 post-term *see* post-term pregnancy  
 preconception care *see* preconception care  
 psychiatric illness and *see* psychiatric disorders  
 screening during *see* prenatal testing  
 spontaneous loss (miscarriage) *see* spontaneous abortion  
 termination (induced) *see* therapeutic abortion  
 third trimester bleeding *see* third trimester bleeding  
 unplanned 81  
 epidemiology 275, 286  
 prevention *see* family planning  
 psychotic disorders and 246  
 weight gain 87  
*see also* fetus; labor/delivery
- pregnancy-associated plasma protein A (PAPP-A)  
 definition 65  
 prenatal testing 66  
 pregnancy-induced hypertension *see* pre-eclampsia–eclampsia syndrome  
 pregnancy wheel 265  
 Premarin (conjugated equine estrogen) **430**
- premature babies *see* preterm/premature babies  
 premature ovarian failure (POF) 381, 407, 423, 426  
 breast cancer and 351  
*see also* menopause
- premature rupture of membranes (PROM) 136, 137, 182, 183, 191–202  
 cervical length and 192, 192  
 definition 191  
 diagnosis 191–192, 192  
 history/chief complaint 195  
 laboratory evaluations 191, 196, 196–197  
 physical examination 196  
 epidemiology/prevalence 192  
 etiology/pathophysiology 192–193  
 laboratory investigation 186, 191  
 management 193, 197–199  
 antibiotics 198, **200–201**  
 biophysical profiles 197–198  
 conservative 197, 198  
 fetal assessment and 198  
 labor induction 198  
 near term 198–199  
 steroids 198  
 WHO flowchart 197, 197

- multifetal pregnancy and 175  
 preterm delivery risk 197
- premenopause 421  
   adnexal mass evaluation 477, **478**  
   physiology 423
- premenstrual dysphoric disorder (PMDD)  
   definition 415  
   diagnosis 415–416
- premenstrual syndrome (PMS)  
   415–420  
   definitions 415  
   diagnosis **415**, 415–416  
     history/chief complaints 416  
     symptom charts 416, **417**  
   epidemiology/prevalence 416  
   etiology/pathophysiology 416, 418  
   treatment 417–419  
     dietary interventions 418  
     drug treatments 418  
     ineffective/unproven 418–419  
     life-style changes 417–418
- prematuration, fragile X syndrome 50
- prenatal care *see* antepartum care
- prenatal history, hemolytic disease 161, **162**
- prenatal testing 50–52, 65–70, 86, **88**  
   best evidence **54**, **69**  
   biochemical markers 66, **69**  
   congenital syphilis 228  
   definitions 65  
   diagnostic tests 51, 68–69  
   first trimester 50–51, 66, 67, 67  
   first vs. second trimester 67, 67  
   integrated *see* integrated prenatal screening (IPS)  
   invasive tests 51, 68–69  
   laboratory techniques used 52–53, 68  
   multifetal pregnancy 174  
   noninvasive tests 51–52  
   nuchal translucency 51, 66, 66  
   second trimester 66, 67, 67  
   strategies 50–51, 65–68  
   timing/ethical issues 67  
   *see also specific techniques*
- presacral neurectomy  
   chronic pelvic pain management 328  
   endometriosis management 321
- prescription drugs *see* drug(s)
- preterm labor/birth 135–145, 179–180  
   definitions 135, 179  
   diagnosis 136, 179–180  
     algorithm for **142**  
     cervical length and 141, 142, 145, 185  
     history/chief complaints 140, 183  
     laboratory tests (fetal fibronectin) 141–142, 179, **180**, 186, **189**  
     physical examination 141, 184–185  
     symptoms/signs 140, 183  
     ultrasonography 142, 185  
   epidemiology/prevalence 136, 136, 137, 181
- etiology/pathophysiology 136–140, **138**, 182  
   cervical insufficiency 139  
   drug/alcohol abuse and 235  
   endocrine system and 139–140, **148**, 236  
   immunological/allograft rejection 139  
   infection/inflammation 137–138, **138**, 186, 236  
   multiple gestations and 136, 139  
   obstetric practices and 136, 182  
   PROM *see* premature rupture of membranes (PROM)  
   risk factors 137, 137, **141**, **180**  
   smoking and 235  
   socioeconomic status and 136, 137  
   uterine ischemia 138  
   uterine overdistension 138–139
- management 142–145, 184, 186–188  
   antibiotics 142–143, 188, 198, **200–201**  
   asymptomatic, high risk women 145  
   emerging treatments 188  
   hospitalization 142, 174  
   main goals 143  
   multifetal pregnancy and 174–175  
   PROM *see* premature rupture of membranes (PROM)  
   steroids *see* steroid-induced lung maturation  
   tocolytics *see* tocolytic therapy
- neonatal complications 137
- preventative measures 235–236
- triage assessment 183, 184  
*see also* preterm/premature babies
- preterm/premature babies  
   ethical dilemmas and 522  
   morbidity and 136–137, 182  
   mortality and 136, 136, 233, 235  
   respiratory problems 107–108  
     antenatal steroids and prevention  
       *see* steroid-induced lung maturation  
   thermoregulation 108, 112, 112  
   *see also* preterm labor/birth
- preventative medicine, medical economics and 503, **503**
- primary ovarian failure *see* premature ovarian failure (POF)
- privileges, legal issues 528
- professional liability, medical economics and reform 504
- progesterone  
   cholestasis and 255  
   corpus luteum 36  
   ectopic pregnancy and 121  
   ovulation role 35–36, 36, 404  
   PMS/PMDD and 418  
   preterm labor/birth and 140
- progestin-only pill 278, **278**  
   endometriosis-related pelvic pain and 319, **319**  
   menopausal hot flashes and 427
- progestin withdrawal test 379–380
- prolactinomas, secondary amenorrhea 380–381
- prolactin-secreting pituitary tumors, secondary amenorrhea 380–381
- prolapse (pelvic organ) 331–332, 332
- prostaglandins  
   dysmenorrhea 398  
   labor induction 268  
   ovulation role 35
- proteinuria, pre-eclampsia–eclampsia syndrome, diagnostic requirement 149, **149**, 152
- protozoan infections  
   pregnancy and 229–231  
   vaginitis and 300–301  
*see also specific infections/organisms*
- protraction disorder, definition 146
- psychiatric disorders 8–9  
   breast-feeding and medications 247–248, **248**  
   following sexual assault 497, **498**  
   genetics 242  
   menopause and 426  
   postpartum 248  
     mood disorders *see* postpartum mood disorders  
   pregnancy and 9, 241–250  
     addressing psychiatric issues during 243–246  
     family planning and 241  
     medications and 244–245, **245**, 247–248  
     postpartum complications 242  
     risk factors for fetus 242, 244, **244**  
     risk factors for mother 242  
     *see also* postpartum mood disorders  
   *see also specific disorders*
- psychosocial aspects of infertility 411
- psychosocial support  
   following sexual assault 497  
   postpartum mood disorders 248
- psychotic disorders, pregnancy and 246
- PTEN mutations, endometrial cancer and 436, 472
- pubarche, definition 31
- puberty 4  
   definition 31  
   developmental milestones 4, 4  
   menses initiation *see* menarche  
   weight/nutritional effects 5
- puerperal endometritis  
   definition 212  
   delivery and treatment 215  
   diagnosis 212  
   epidemiology/prevalence 213  
   etiology/pathophysiology 213
- pulmonary hypertension, antidepressant drugs and 245
- pulse oximetry, fetal 97
- Q**  
 quad test 66



- R**
- race *see* ethnicity/race
- RADAR, domestic violence assessment 496
- radial scarring, breast 346
- radiotherapy  
breast cancer treatment 356  
cervical cancer therapy 458  
endometrial cancer 474
- raloxifene  
bone density effects 428  
breast cancer prevention 352–353, **358**
- rape *see* sexual assault
- recessive traits/disorders 49
- reciprocal translocations 47–48
- rectocele (posterior prolapse) 331, 332
- rectovaginal examination 19, 20
- recurrent abortion 131  
definition 127  
incidence 128
- renal function, maternal changes during pregnancy 76
- reproductive hormones  
androgens *see* androgen(s)  
breast cancer risk 351–352, **357–358**  
estrogens *see* estrogen(s)  
polycystic ovary syndrome and 388, 388–389  
*see also specific hormones*
- reproductive risk factors, breast cancer 351
- reproductive system  
anatomy 28–30  
definitions 25  
development/embryology *see* genital embryogenesis  
hormones *see* reproductive hormones  
*see also specific structures/components*
- respiratory acidosis, definition 91
- respiratory distress syndrome (RDS) 108, **108**
- respiratory system  
fetal 107  
maternal changes during pregnancy 76, 76, 255  
neonatal transition period 107–108  
*see also* steroid-induced lung maturation
- retinoblastoma protein (Rb), HPV effects 436, 455
- retrograde menstruation, endometriosis and 315, 316
- rhabdomyoma 16
- rhesus isoimmunization 159–166  
definition 159  
diagnosis 159  
Doppler ultrasonography 160, **164–165**  
history/chief complaint 161–162, **162**  
invasive testing 162, 163, 163–164  
laboratory evaluation 162–164  
physical examination 162
- epidemiology/prevalence 160, **160, 161**  
etiology/pathophysiology 160  
risk factors **162**  
fetal hemolysis 159, 159  
IgM vs. IgG immunoglobulins 162–163  
'irregular antibodies' 160, **160**  
prophylaxis/antepartum care 86–87  
RhoGAM antibody therapy 159, 160  
therapeutic abortion and 286  
treatment 164  
fetal blood transfusion 163, 163, 164  
neonatal management 164
- rhythm method 276
- ring chromosomes 48, 48–49
- ritodrine, as tocolytic agent 187, 235
- Robertsonian translocation(s) 43, 48, **48**
- robotic surgery, myomectomy 371–372, 466
- S**
- sacrocolpopexy 332, 332
- saline infusion sonohysterography 375
- salpingectomy, ectopic pregnancy management 122
- salpingitis, *Chlamydia trachomatis* 306
- salpingo-oophorectomy, risk reducing bilateral 353, 481
- salpingostomy, ectopic pregnancy management 122
- salpingotomy, ectopic pregnancy management 122
- sarcomas, uterine 467
- Sarcoptes scabiei* 449
- scabies, vulval lesions 449
- Schiller test 21
- schizophrenia, pregnancy and 246
- second trimester screening 66  
first trimester vs. 67, 67
- seizures *see* convulsions
- selective estrogen receptor modulators (SERMs), bone density effects 428
- selective progesterone receptor modulators (SPRMs), uterine leiomyomas and 463, **468**
- selective serotonin reuptake inhibitors (SSRIs)  
menopausal mood disorders 426  
PMS/PMDD management 418, **419**  
pregnancy and 244–245  
PTSD following sexual assault **498**
- semen, infertility tests 404–405, **405**
- sentinel bleeding 214
- sentinel lymph node biopsy 355, 355–356
- septic abortion 127, 129
- serological evaluation(s)  
antepartum care 86  
herpes simplex virus diagnosis 222  
HIV infection 224  
preconception care 84  
toxoplasmosis 230
- serotonin, PMS and PMDD 416, 418
- Sertoli–Leydig cell tumor 483  
virilization and 394
- sex chromosome(s)  
definition 42  
genetic disorders  
Mendelian disorders 49  
numerical abnormalities 44, 45–47, 46  
*see also specific disorders*  
sex cord–stromal tumors 482–483  
*see also specific types*
- sex differences  
health issues and 3  
mental health 8, 9, 243  
puberty and 4
- sex hormone binding globulin (SHBG), polycystic ovary syndrome and 391
- sex-specific behaviors 487
- sex therapy, female sexual dysfunction therapy 491
- sexual arousal 488  
disorders 490
- sexual assault 496–498  
comprehensive care 497  
definition 496  
epidemiology/prevalence 496  
history taking/examination 497  
treatment 497
- Sexual Assault Nurse Evaluation (SANE) program 497
- sexual aversion disorder (SAD) 490
- sexual dysfunction  
common problems in women 489–490  
general population 488, **488**  
history taking 488–489, **489**  
menopause and 425–426  
pain and 490  
postpartum 492  
treatment 491–492  
*see also specific disorders*
- sexual history 17, 305, 488–489  
medical history and 489  
multifaceted approach **489**  
open-ended questions 488  
physical exam and **489**  
sexual function questionnaire 489  
*see also* sexually transmitted diseases (STDs)
- sexual identity 487
- sexuality 487–494  
adolescents 492  
chronic illness and 492  
dimensions 487  
older adults 492–493  
sexual identity 487  
sexual responses 487–488  
*see also* sexual dysfunction; *specific dimensions*
- sexually transmitted diseases (STDs) 305–310  
adolescents 492  
bacterial 305–307, **308**, 308–309  
ethical issues 524

- maternal mortality and 238  
 non-ulcerative lesions 305–306  
 risk factors 305  
 screening 305  
   Chlamydia 306  
   HIV 224, 520–521  
   sexual assault and 497  
   syphilis 228  
 ulcerative lesions 306–309, **308**  
 viral 307, **308**, 309  
*see also* pelvic inflammatory disease (PID); *specific infections/organisms*
- Sheehan syndrome, secondary amenorrhea 381
- shoulder dystocia 266, 266, 269
- sinusoidal patterns, fetal heart rate 95–96, 96
- skin tag, vulval 448
- smoking  
 fertility and 409  
 fetal growth restriction and 182–183  
 preconception care and pregnancy 82  
 preterm birth/perinatal mortality and 235  
 primary ovarian failure 423
- social factors/issues  
 contraception and 275  
 health care provision and 501–506  
 infertility 411  
 preterm birth/labor and 136, 137  
*see also* medical economics
- somatarche 4
- Southern blotting, prenatal testing 53, 53
- speculoscopy, cervical screening and 456
- speculum examination 18–19, 19
- sperm  
 donation 406  
 fertilization of ovum 37
- spermicides 277
- spinal manipulation, dysmenorrhea and 401
- spirometry, asthma diagnosis 252, 252
- spironolactone, hirsutism management 394, 394
- sponge, contraceptive 277
- spontaneous abortion 127–134  
 definitions 127  
 diagnosis 129–130  
 ectopic pregnancy vs. 121, 122  
 etiology/pathophysiology 128–129  
 endocrine disorders 129  
 fetal defects 129  
 genetic 128, 128  
*see also* chromosome abnormalities  
 infection and 129  
 placenta and 129  
 procedure-related 129  
 recurrent abortion 131  
 structural problems 128, 129, 131  
 thrombosis 128, 131  
 toxins/exposure-related 129  
*see also specific etiologies/risk factors*
- incidence 128  
 recurrent abortion 127, 128, 131  
 therapeutic abortion association 289  
 treatment  
   expectant vs. medical **132**  
   first vs. second trimester 130  
   outcomes **132**  
   post-treatment evaluation/counseling 131–132
- squamous cell carcinoma, Bartholin gland 447–448
- Stages of Reproductive Aging Workshop (STRAW) staging system 421–422, **422**, 425
- standards of care 528
- staphylococcal infections, vulval abscess 449
- stem cells, cancer 438
- stepwise sequential testing 68
- sterilization  
 ethical dilemmas 523–524  
 female (tubal ligation) 280, 280–281, 281, 365  
 male (vasectomy) 281
- steroid-induced lung maturation 142, 143, 174, 186, 188, 235  
 pre-eclampsia management 153  
 PROM management and 198
- 'strawberry cervix' 300, 300
- stress incontinence 333  
 diagnosis 333–334, 334  
 management 334–335, 335, **337**
- stress, infertility and 411
- suction curettage 286
- suicide ideation 8–9
- supracervical hysterectomy (SCH) 367, **375**
- surgery, gynecological *see* gynecological surgery
- surgical menopause 427
- symphysiotomy, obstructed births 237–238
- syngamy 37
- syphilis 306–307  
 clinical features 227–228, 306  
 congenital syphilis 228, **228**, 307  
 latent disease 306  
 late syphilis 227  
 late/tertiary syphilis 227–228, 306–307  
 primary syphilis 227, 227, 306  
 secondary syphilis 227, **227**, 306  
 diagnosis **228**, 228–229, **229**, 307  
 following sexual assault 497  
 infection staging 226  
 pregnancy and 226–229  
   fetal infection routes 227  
   impact of disease on 227  
   management 229, 229  
   preconception care and evaluation 84  
   prenatal testing 228  
 transmission 226, 306  
 treatment 307  
   pregnancy and 229, 229  
 syphilitic chancre 227, 227, 306
- T**
- tachycardia, fetal 92
- tachypnea, definition 107
- tachysystole 100
- tamoxifen, breast cancer prevention 352–353, **358**
- TCu380A (Paragard) IUD 279
- teratogens, prescription drugs 82, **83**, 244
- teratomas 481
- terbutaline, as tocolytic agent 187
- terminal illness, medical economics and 503
- testosterone  
 sexual dysfunction and 425, **493**  
 Turner syndrome 384
- thecomas 482
- thelarche, definition 31
- therapeutic abortion 285–292  
 complications 287, 288–289  
 confirmation of success 287  
 counseling 286  
 definition 285  
 epidemiology 285–286  
 ethical issues 285, 522  
 failure 289  
 historical aspects 285  
 history/examinations 286  
 legal issues 285  
 long-term outcomes 289  
 methods/techniques  
   best evidence (clinical wisdom) **289–290**  
   first trimester 286–287, **287**  
   labor induction 288  
   medical abortion 286–287, **287**, **287**, **290**  
   risks 286, 287  
   second trimester 287–288  
   surgical methods 286, 287, **287**, 287  
   timing of 288  
   unsafe (illegal) 285–286  
   *see also specific procedures*
- thermal neutral zone 109, 109
- thermoregulation, neonatal transition 108–110, 109, 110  
 neonatal care and 111–112, 112
- thermoregulatory behaviors, neonatal period 110
- third trimester bleeding 191–202  
 definitions 191  
 diagnosis 192  
   history/chief complaint 195  
   laboratory evaluation 197  
   physical examination 196  
 epidemiology/prevalence 192  
 etiology/pathophysiology 193–194  
 minor vs. serious causes 192  
 management 199, 215  
   delivery 215–216  
   outpatient vs. inpatient 215  
 mortality associated 191  
 postpartum hemorrhage and 214, 215  
*see also* postpartum hemorrhage  
*see also specific causes*

- threatened abortion, definition 127  
 3-IQ questionnaire 333, 334  
 three delays model 528, 528  
 thrombocytopenia, definition 219  
 thrombophilia  
 definition 16  
 pre-eclampsia/eclampsia and 155  
 spontaneous abortion and 128, 131  
 thyroid disorders 6  
 definition 251  
 hyperthyroidism *see* hyperthyroidism  
 hypothyroidism *see* hypothyroidism  
 postpartum 257  
 pregnancy and  
 chief complaints/examination 258–259  
 diagnosis 254  
 epidemiology/prevalence 254  
 etiology/pathogenesis and 257  
 laboratory evaluation 260  
 management 262  
 preconception care and 84  
 spontaneous abortion and 129  
*see also specific diseases*  
 thyroid gland  
 disorders *see* thyroid disorders  
 fetal 78  
 ‘thyroid storm’ 259  
 tobacco, preconception care and pregnancy 82  
 tocolytic therapy 143, 186–188, 235  
 agents used 143, 186, **186**  
 emerging treatments 188  
 second-line drugs 188  
 mechanism of action **143**  
 multifetal pregnancy and 175  
 side effects/contraindications **144, 186, 187, 187**  
*see also specific agents*  
 total abdominal hysterectomy (TAH) 367  
 toxins, spontaneous abortion and 129  
*Toxoplasma gondii* 229  
 life cycle 229  
*see also* toxoplasmosis  
 toxoplasmosis 229–231  
 congenital *see* congenital toxoplasmosis  
 diagnosis 230  
 preconception care and evaluation 84, 230  
 primary prevention 230, **230**  
 screening controversy 230  
 transmission 230  
 transcutaneous electrical nerve stimulation (TENS)  
 back pain and 260, 260–261  
 dysmenorrhea treatment 401  
 transgendered individuals 487  
 transient hypertension (in pregnancy) 205, 208  
 transition period, definition 107  
 trans-sexuals 487  
 transvaginal ultrasonography (TVUS)  
 chorionicity assessment 171  
 placenta previa diagnosis 192  
 polycystic ovary syndrome  
 diagnosis 388, 388, 391  
 postpartum hemorrhage 215  
 spontaneous abortion diagnosis 129  
 trastuzumab, breast cancer treatment 356  
*Treponema pallidum* 226, 307  
*see also* syphilis  
*Trichomonas vaginalis* 300, 300  
 trichomoniasis 300–301  
 causative organism 300, 300  
 clinical features/diagnosis 300, 300–301  
 epidemiology 300  
 sexual activity and 300  
 treatment 301  
 trinucleotide repeat disorders 49–50  
 triple test 66  
 triplets, labor/delivery 178  
 triple X syndrome (47,XXX) 46  
 trisomies 44–46  
 definition 65  
 isochromosomes and 48  
 spontaneous abortion and 128, 128  
*see also specific conditions*  
 trisomy 13 (Patau syndrome) 44–45, 45  
 trisomy 18 (Edwards syndrome) 45, 45  
 trisomy 21 (Down syndrome) 44  
 isochromosomes and 48  
 karyotype 68  
 maternal age and 44, 44, 65, 68  
 phenotypic features 44, 44  
 prenatal screening 50–51, 65  
 CVS 68  
 serum markers 66, **69**  
*see also* prenatal testing; *specific methods*  
 spontaneous abortion and 128, 128  
 trochanteric belts 261  
 trophoblast 38  
 tubal ligation 280, 280–281, 281, 365  
 tubal pregnancy *see* ectopic pregnancy  
 tubo-ovarian abscess 313  
 tumor(s)  
 immunology 438  
 pituitary, secondary  
 amenorrhea 380–381  
 virilization and 394, 395  
*see also* cancer; *specific types/locations*  
 tumor suppressors, HPV effects 436, 455  
 Turner syndrome 44, 46, 47  
 breast development 383–384  
 growth hormone therapy 383  
 isochromosomes and 48  
 primary amenorrhea 383–384  
 primary ovarian failure 423  
 ‘twin-peak sign’ 172  
 twins  
 complications 170, 170–171  
 epidemiology 168, **169**  
 etiological factors 169  
 fetal position and delivery 176–177, 177  
*see also* multifetal pregnancy  
 twin-to-twin transfusion syndrome 170, 170–171  
 ‘two-cell, two-gonadotropin theory’ 33–34, 34
- U**  
 ulcers, vulval lesions 449  
 ultrasonography 22–23  
 adnexal mass evaluation 477  
 ovarian cancer 479  
 breast mass evaluation 345  
 cholecystitis diagnosis 253, 253  
 fibroid diagnosis 371  
 hydatidiform mole diagnosis 441–442  
 infertility diagnosis/evaluation 405  
 MRI-guided 467  
 obstetric  
 due date and 265  
 ectopic pregnancy diagnosis 119, 121, 121  
 fetal growth restriction assessment 185–186, 186  
 intrapartum fetal surveillance 96  
 multifetal pregnancy and 168, 168, 171–173, 173, 174  
 nuchal translucency 51, 65, 66, 66  
 postpartum hemorrhage 214–215, **217**  
 preterm labor/birth and 142, 185, 192, 192  
 rhesus isoimmunization and 159, **160, 164–165**  
 spontaneous abortion diagnosis 129  
 standard antepartum care 86  
 vasa previa and 196  
 uterine leiomyomas 462  
*see also specific modalities*  
 ultrasound biometry, fetal growth restriction 185  
 unconjugated estriol  
 definition 65  
 prenatal testing 66  
 United Nations Population Fund, three delays model 528, 528  
 urge incontinence 333  
 diagnosis 333–334, 334  
 management 335–336  
 urinary incontinence 333–336  
 diagnosis 333–334, 334  
 incidence 333  
 management 12  
 bulking injections **337**  
 medical 335–336  
 nonsurgical 334–335, 335–336  
 stress incontinence 334–335, 335, **337**  
 surgical 335, 335  
 menopause and 12, 426  
 pathogenesis 333  
 subtypes/classification 333  
*see also specific types*

- urinary tract  
infections 336  
pelvic pain and **325, 326**
- urodynamics 333–334
- uterine artery  
embolization, uterine leiomyoma management 7, 466, **468**  
occlusion, uterine leiomyoma management 466–467
- uterine atony  
definition 212  
diagnosis 212  
epidemiology/prevalence 213  
etiology/pathophysiology 214  
management 216, **216, 217**  
therapeutic abortion and 289
- uterine bleeding, dysfunctional 384–385  
endometrial cancer and 472  
polycystic ovary syndrome and 394  
uterine leiomyomas and 462  
uterine sarcomas and 474  
*see also specific types/causes*
- uterine contractions  
dysmenorrhea 398  
parameters 99–100  
pharmacological inhibition 401
- uterine fibroid embolization (UFE) 7, 466
- uterine ischemia, preterm labor/birth and 138
- uterine leiomyomas 7–8, 461–470  
definition 16, 370  
diagnosis 7, 371, 462  
dysmenorrhea and 399  
epidemiology/incidence 7, 371, 461  
etiology/pathophysiology 461, **461, 461**  
infertility and 408  
locations 370, 370, 461, 461  
management 7–8, 371, 462–467  
embolization/occlusion 466–467, **468**  
hysterectomy vs. other methods 366, **468**  
medical treatment 462–463, **468**  
myomectomy *see myomectomy*  
surgical treatment 463–467, **468**  
treatment options 462, **463**  
*see also specific methods*  
necrosis 462, 466  
sarcomas vs. 467  
symptoms/signs 7, 462
- uterine leiomyosarcomas 474–475
- uterine nerve ablation, dysmenorrhea and 401
- uterine overdistension, preterm labor/birth and 138–139
- uterine perforation  
IUDs and 280  
therapeutic abortion and 289
- uterine rupture  
definition 191  
diagnosis  
history/chief complaint 195  
physical examination 196  
epidemiology/prevalence 192  
etiology/pathophysiology 194, **194**  
management 199
- uterine sarcomas 467, 474–475
- uterine suspensory ligaments 28, 29
- uterogenic agents 236–237  
postpartum hemorrhage management **239**  
*see also specific drugs*
- uterus  
anatomy 28, 29, 461, 461  
bimanual examination 19, 19  
'boggy,' adenomyosis and 321  
cervix *see cervix*  
hypocontractile 146  
infertility and 408  
lesions  
fibroids *see uterine leiomyomas*  
sarcomas 467, 474–475  
multifetal pregnancies and 170  
prolapse 331, 332, 332  
secondary amenorrhea and 382  
structural abnormalities  
developmental 25, **25, 27**  
infertility and 408  
spontaneous abortion and 128, 129  
*see also entries beginning utero-/uterine; specific conditions/abnormalities*
- V**
- vaccination  
antepartum care 86–87  
human papilloma virus (HPV) 4–5, 455  
medical economics, developed countries 503, **503**
- vacuum aspiration 286
- vacuum extraction 105
- vagina  
bimanual examination 19, 19  
biopsy 21  
common developmental abnormalities **25**  
inflammation *see vaginitis*  
lesions 447–452  
intra-epithelial neoplasia 450–451  
malignant *see vaginal cancer*  
vaginal wall cysts 448  
menopause and 425, 426, 428  
normal physiology/flora 293–294  
rectovaginal examination 19, 20  
speculum examination 18  
*see also entries beginning vaginal*
- vaginal bleeding, molar pregnancy 442
- vaginal cancer 451  
premalignant lesions 450–451  
surgical staging and survival 451, **451**
- vaginal delivery  
HIV infection and 224  
multiple births 176–177  
placenta previa and 199
- vaginal discharge  
bacterial vaginosis 298, 298  
fallopian tube cancer 483  
normal 293–294  
trichomoniasis 300  
vulvovaginal candidiasis 296, 296
- vaginal dryness, therapy 491
- vaginal fluid, PROM diagnosis 196
- vaginal intra-epithelial neoplasia (VAIN) 450–451
- vaginal introitus, definition 107
- vaginal slings 335, 335
- vaginal surgery 363–364  
hysterectomy 367–368, 369
- vaginal symptoms, menopause and 425
- vaginal uterine artery occlusion, uterine leiomyoma management 466–467
- vaginal wall cysts 448
- vaginismus 490
- vaginitis 293–301  
definition 293  
diagnosis 294–296  
clinical features 294, **294**  
history 295  
office analysis **295, 295–296**  
physical examination 295  
epidemiology/prevalence 293  
etiology/pathophysiology 293–294  
infectious 293, **293, 294, 296–301**  
noninfectious 293, **293, 301**  
*see also specific organisms/conditions*  
types 296–301
- valacyclovir, HSV transmission reduction in discordant couples **309**
- vasa previa  
definition 191, 212  
diagnosis 212  
history/chief complaint 195  
physical examination 196  
epidemiology/prevalence 213  
etiology/pathophysiology 193–194, 194, 214  
management 199, 216
- vascular endothelial growth factor (VEGF), angiogenesis and cancer 437–438
- vasectomy 281
- vasospasm, pre-eclampsia–eclampsia syndrome 151–152, 205
- vertical transmission  
definition 219  
HIV 224  
toxoplasmosis 230
- vestibulodynia 490
- violence  
domestic 495, 495–496  
sexual assault *see sexual assault*
- viral infections  
cervical cancer and *see human papilloma virus (HPV)*  
pregnancy and 219–225  
prophylactic treatment following sexual assault 497

- sexually-transmitted diseases 307, **308**, 309  
*see also specific organisms/infections*
- viral titer, definition 219
- viremia, definition 219
- virilization 394–395  
 Sertoli–Leydig cell tumors 483
- vitamin D supplements, menopause 428
- vitamin K prophylaxis 112
- vomiting, pregnancy 256
- vulva  
 biopsy 21, 450  
 inflammation *see* vulvitis  
 lesions 447–452  
 intra-epithelial neoplasia 449–450  
 malignant *see* vulvar cancer  
 palpable 447–448  
 pigmented 448  
 pustules/vesicles 449  
 ulcers/fissures 449  
*see also specific types/causes*  
 pain 302  
*see also entries beginning vulvo-/vulvar*
- vulvar cancer 450  
 etiologies 450, **452**  
 premalignant lesions 449–450  
 staging 450, **450**  
 surgical management 450
- vulvar dermatoses 302–303  
 cancer link 450
- vulvar intra-epithelial neoplasia (VIN) 449–450
- vulvitis 301–303  
 clinical features/diagnosis 302–303  
 definition 301  
 etiology/pathophysiology 301–302  
 treatment options 302, 303  
*see also* vaginitis
- vulvodynia 490
- vulvovaginal candidiasis 296–298  
 classification 297, **297**  
 clinical features/diagnosis 296–297  
 laboratory tests 296, 296–297  
 vaginal discharge 296, 296  
 overgrowth pathophysiology 296  
 recurrent 297, 298, **303**  
 risk factors 296  
 treatment 297–298  
 complicated disease 297–298  
 recurrent disease 298, **303**  
 symptomatic relief 297  
 uncomplicated disease 297, **297**
- W**
- weight control  
 antepartum care and 87  
 multifetal pregnancy 173  
 birth to adolescence 5
- hormonal contraception and 278  
*see also* nutrition; obesity
- ‘whiff’ test 295–296
- withdrawal, contraception and 276
- Women’s Health Initiative study (WHI)  
 HRT and breast cancer 11  
 HRT benefits 429, **430**
- World Health Organization (WHO)  
 contraception guidelines 5, **6**  
 post-term pregnancy definition 265  
 PROM management  
 recommendations 197, 197  
 Surgical Checklist 504, **504–505**
- X**
- X-chromosome disorders  
 fragile X syndrome 50, 426  
 numerical abnormalities 45–47, 46, 47  
 premature ovarian failure 381, 423  
 primary amenorrhea 382  
 recessive disorders 49  
*see also specific conditions*
- X-linked inheritance 49
- Z**
- Zestra, sexual dysfunction management 492
- zygote 37, 38